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C. Inhibition effects by targeting DNA, pRNA, gp16 or ATP
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METHOD FOR DESIGNING COMPOUNDS
AND COMPOSITIONS USEFUL FOR
TARGETING HIGH STOICHIOMETRIC
COMPLEXES TO TREAT CONDITIONS,
INCLUDING TREATMENT OF VIRUSES,
BACTERIA, AND CANCERS HAVING
ACQUIRED DRUG RESISTANCE

tance of cancer has escalated and has partially contributed to
the -600.000 deaths in the USA in 2012 [37]. HIV drug
resistance has also become a major issue [38]. Many common pathogens have become resistant to current drug treatments, with new infectious diseases on the rise. The use of
multidrug-resistant agents in biological weapons has created
a previously unrealized challenge [39]. Thus, there is a need
to develop new treatment strategies to combat drug resistance with new drug development methods.
The first FDA-approved drug to treat multidrug-resistant
tuberculosis, bedaquiline, follows a new mechanism of
inhibiting the bacterial ATP synthase of M. tuberculosis and
other mycobacterial species, but had little activity against
other bacteria [40]. To combat multidrug resistance in cancer, several approaches have been explored. One method is
to target components that are highly important for the
growth of the biological entity [41,42]. Another approach
uses nano-drug delivery carriers that are expected to
enhance the binding efficiency of drugs to cancer cells[43,
44,45,46], or cocktail therapy [47]. A third approach is to
develop new combinational drugs with higher potency by
acting on multiple targets [48,49]. This involves identifying
multiple targets that when treated leads to a synergetic effect
and optimizing the design of multi-target ligands[50].
The approach of developing highly potent drugs through
targeting protein or RNA complexes with high stoichiometry
has never been reported due to challenges in comparing
efficacies of two drugs that can be confused by target
essentiality with binding affinity. For instance, if two drugs
target two stoichiometrically different targets, it becomes
extremely difficult to prove whether the difference in drug
efficiency is due to differences in their target binding affinity
or essential level in the growth of the biological organism.
In order to quantify effects from targeting biocomplexes of
different stoichiometry, a well-studied multicomponent system is required that allows empirical comparison of functional inhibition of individual components that are composed of different number of subunits.
An example of one nanobiomachine is the dsDNA translocation motor, for which the ATPase protein is a pivotal
component that assembles into a hexameric ring structure
and translates the action of ATP binding and hydrolysis into
mechanical motion to translocate DNA physically. The DNA
packaging motor of bacteriophage phi29 (FIG. lA) [9,51,
52,53] is composed of three essential co-axial rings: 1) a
dodecameric connector ring located at the vertex of the viral
procapsid; 2) a hexameric packaging RNA (pRNA) ring [52]
bound to the N-terminus of the connector [54], and 3) a
hexameric ring of ATPase gp 16 attached to the helical region
of pRNA [10,19,55], powered through the hydrolysis of ATP
resulting in DNA packaging. The use of Yang Hui's Triangle
(FIG. lB) or binomial distribution to determine the stoichiometry of the pRNA was first reported in 1997 [56]. The use
of similar mathematical methods to determine the stoichiometry of the protein subunits has also been reported more
recently [51]. The copy number of ATP molecules required
to package one full phi29 genomic dsDNA was predicted to
be 10000 [57]. It has recently been shown that this hexameric motor uses a revolution mechanism without rotation to
translocate its genomic DNA [10,19,33,35,36,58,59].
Herein, the present inventors propose that the inhibitory
efficiency of a drug is related to the stoichiometry of its
targeted biocomplex; the higher the stoichiometry of the
target complex, the more efficient the drug. This can lead to
the development of potent therapeutics against high-stoichiometric biomachines or biocomplexes as drug targets.
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INTRODUCTION
Bacteria, viruses and cells contain biocomplexes and
nanomachines composed of multiple subunits, such as biomotors [1,2,3,4], pumps [5], exosomes [6,7,8], valves [9,10,
11], membrane pores [12,13,14,15], chaperonins[16],
PCNA [17], ATPase [18,19], and tubes [20]. From a nanobiotechnological standpoint, these nanomachines can be
used and converted to build sophisticated nano-devices
including molecular sensors [21,22,23], patterned arrays,
actuators [24], chips, microelectromechanical systems
(MEMS) [25], molecular sorters [26], single pore DNA
sequencing apparatus [12,13,21,27] or other revolutionary
electronic and optical devices [28,29]. From a pharmaceutical standpoint, these multi-subunit biocomplexes or nanomachines have a potential for use as drug targets for therapeutics, as well as diagnostic applications such as pathogen
detection, disease diagnosis, drug delivery, and treatment of
diseases [22,23,30,31]. In the ASCE (Additional Strand
Catalytic E) family including the AAA+ (ATPases Associated with diverse cellular Activities) and the FtsK-HerA
superfamily in bacteria, viruses and cells, there are nanomotors that perform a wide range of functions [19,32,33]
critical to chromosome segregation, bacterial binary fission,
DNA/RNA and cell component transportation, membrane
sorting, cellular reorganization, cell division, RNA transcription, as well as DNA replication, riding, repair, and recombination [1,34,35,36]. One of the directions of NIH Roadmap is to utilize these cellular nanomachines and
biocomplexes for biomedical applications.
Acquired drug resistance has become a major reason for
failure treatment of a range of diseases, i.e., the chemotherapy for cancer, bacterial or viral infections. Drug resis-
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This method was employed as described herein by using
a mutant subunit as the drugged inactive target to calculate
the theoretical inhibition efficiency via binomial distribution, and compared with experimental data from a defined in
vitro viral assembly system. Since biomotors share certain
common structures and operation mechanisms [1,36,59,60],
the approach in drug development reported here has general
applications especially in developing new generations of
drugs for combating the rising acquired drug resistance in
viruses, bacteria, and cancers [38,61,62].

FIG. lC is an illustration ofZ=6 and K=l, drug targeting
any one subunit of the complex will block its activity.
FIG. lD is an AFM image of hexameric re-engineered
pRNArings.
FIG. lE is a 3D structure of hexameric pRNA ring top
view and side view from the crystal structure of3WJ (PDB
ID: pRNA 3WJ, 4KZ2).
FIG. lF is a crystal hexameric structure of AAA+ Protein
CbbX withtop view and side view [85] (PDB ID: CbbX,
3Znh, http://www.ebi.ac.uk/pdbe/emdb/).
FIG. lG is a structure of the hexameric AAA+ molecular
machine ClpC with adaptor protein MecA. [86] (PDB ID:
MecA-ClpC, 3PXG).
FIGS. 2A-2C show a theoretical plot (with variable Z) and
empirical data illustrate inhibition efficiency with drug targeting to genomic DNA (Z-1 ).
FIG. 2A is a gel showing the phi29 genome DNA treated
with endonuclease EcoRl.
FIG. 2B is a plot of virion assembly derived from binomial distribution equation 2, which showed that the DNA
has stoichiometry of 1.
FIG. 2C is a viral assembly inhibition effect of mutant
DNA as model of drugged component with Z=l, showing
the linear relationship to p with low slope.
FIGS. 3A-3C is a theoretical plot (K=l to 6) and empirical
data to illustrate inhibition efficiency with drug targeting
pRNA (Z=6).
FIG. 3A is the sequence and secondary structure of
wild-type pRNA of phi29 DNA packaging motor (upper
panel) and inactive mutant pRNA with 4 bases mutation at
5'end of the DNA translocation domain serving as a model
of drugged inactive pRNA (lower panel).
FIG. 3B is a fitting the phage assembly inhibition result by
inactive mutant pRNA with the theoretical plots derived
from Equation 2 matched with Z=6 and K=l.
FIG. 3C compares the viral assembly inhibition effect by
drugged pRNA at different concentration with the
undrugged pRNA with same dilution factor.
FIGS. 4A-4B shows complete inhibition of viral assembly
in vivo by mutant pRNA as a model of drugged complex
(Z=6).
FIG. 4A shows inactivation of pRNA by introducing a
4-nucleotide mutation at the 3'end.
FIG. 4B shows virion production by wild-type phi29
infection using host cell B. subtilis harboring plasmid
expressing mutant pRNA, wild-type pRNA, or plasmid only.
FIGS. SA-SC show comparison of inhibition efficiency
using targets with different Z values.
FIG. SA shows virion production inhibition effect of
mutant gp16 (Z=6) at different concentration.
FIG. SB shows inhibition efficiency by y-s-ATP with ATP
with high Z value.
FIG. SC compares the virus assembly inhibition effect by
drugged components of DNA, pRNA, gp16 and ATP with
stoichiometry of 1, 6, 6, 10000 respectively.
FIG. 6 shows a relationship between stoichiometry (Z)
and drug targeting level (a combined result of drug binding
efficacy and drug concentration) to reach the inhibition
effect (IC).
FIGS. 7A-7C show the morphology and stoichiometry of
Phi29 DNA packaging motor.
FIG. 7A illustrates a Phi29 DNA packaging motor composed of 1 copy of genomic DNA through a channel
composed of three coaxil rings, a 12 subunit connector, 6
subunit pRNA, 6 subunit ATPase gp16.
FIG. 7B shows a binomial distribution equation with its
coefficient displayed by Yang Hui Triangle.
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SUMMARY
The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
Disclosed herein is a method for designing compounds
useful for treating conditions that can be treated by targeting
high stoichiometric complexes, which is useful, for
example, in designing drugs for against in viruses, bacteria,
and cancers having acquired drug resistance.
As described herein, Phi29 DNA-packaging motor components were used to test the method for use in connection
with targets of different stoichiometries. Virion assembly
efficiency was assayed with Yang Hui's Triangle:
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where Z=stoichiometry, M=drugged subunits in each biocomplex, p and q represent the fraction of drugged and
non-drugged subunits in the population.
As reported herein, inhibition efficiency follows a power
function. When number of drugged subunits to block the
function of the biocomplex K=l, the fraction of uninhibited
biocomplex equals q Thus, stoichiometry has a multiplicative effect on inhibition. Tested targets with a thousand
subunits showed the highest inhibition effect, followed by
those with six and a single subunit. Complete inhibition of
virus replication was found when Z=6.
As disclosed herein, drug inhibition potency depends on
the stoichiometry of the targeted components of the biocomplex or nano-machine. The inhibition effect follows a
power function of the stoichiometry of the target biocomplex.
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BRIEF DESCRIPTION OF THE DRAWINGS
The features of the invention are set forth with particularity in the appended claims. A better understanding of the
features and advantages of the present invention will be
obtained by reference to the following detailed description
that sets forth illustrative embodiments, in which the principles of the invention are used, and the accompanying
drawings of which:
FIGS. lA-lF show the stoichiometry of viral DNA packaging motor
FIG. lA is an Illustration of Phi29 DNA packaging motor
composed of 1 copy of genomic DNA that revolves through
the channel wall (left panel), 6 copies of pRNA, 6 copies of
ATPase gp16 and a connector channel.
FIG. 1B is a Yang Hui Triangle.
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FIG. 7C shows an illustration of Z=6 and K=l, drug
targeting any subunit of a hexameric complex in blocking its
function.
FIG. 8 shows the relationship between the stoichiometry
of homomeric target complex (Z) and target complex inhibition effect (IC).
FIG. 9 compares Phi29 viral assembly inhibition efficiency by targeting components of the system with different
stoichiometries (left panel), DNA with stoichiometry of 1,
ATPase gp16 with stoichiometry of 6 (right upper panel),
pRNA with stoichiometry of 6 (right lower panel), and ATP
with stoichiometry of 10,000. Adapted from ref. [13] with
permission.
FIGS. lOA-lOD shows widespread biomotors or nanomachines that are composed of multisubunit complex.
FIG. lOA shows rotation nanomachine DnaB helicase
which is a hexamer [69] (PDB ID: 4ESV).
FIG. 10B shows rotation nanomachine RecA motor protein which is a hexamer [72] (PDB ID: 1N03).
FIG. lOC shows revolution Phi29 DNA packaging motor
which contains a hexameric pRNA [58].
FIG. lOD shows revolution DNA motor protein FtsK
which is a hexamer [87] (PDB ID: 2IUU).
FIGS. llA-llD show examples ofhomomeric multisubunit complex as drug target for developing potent drugs.
FIG. llA shows tetrameric bpFabI. Tetrameric bpFabiis a
key enzyme in fatty acid synthesis in bacterial, inhibitor
PT155 forms a tetrameric complex with BpmFabI [31]
(PDB ID: 4BKU).
FIG. 11B shows inosine monophosphate dehydrogenase
(IMPDH) [32] (PDB ID: 1AK5). Inosine monophosphate
dehydrogenase is a key enzyme in guanine nucleotide biosynthesis pathway, inhibitors have been developed targeting
the tetrameric IMPDH.
FIG. llC shows a bacterial multidrug efflux transporter
AcrB which forming a homotrimer[91](PDB ID: 11 WG).
FIG. llD shows a multidrug exporter MexB from
Pseudomonas aeruginosa forming a homotrimer[92] (PDB
ID: 2V50).
FIGS. 12A-12F show the stoichiometry of viral DNA
packaging motor
FIG. 12A is an Illustration of Phi29 DNA packaging
motor composed of 1 copy of genomic DNA that revolves
through the channel wall (left panel), 6 copies of pRNA, 6
copies of ATPase gp16 and a connector channel.
FIG. 12B is a Yang Hui Triangle.
FIG. 12C is an illustration of Z=6 and K=l, drug targeting
any one subunit of the complex will block its activity.
FIG. 12D is an AFM image of hexameric re-engineered
pRNArings.
FIG. 12E is a 3D structure of hexameric pRNA ring top
view and side view from the crystal structure of3WJ (PDB
ID: pRNA 3WJ, 4KZ2).
FIG. 12F is a crystal hexameric structure of AAA+
Protein CbbX with op view and side view (PDB ID: CbbX,
3Zuh, http://www.ebi.ac.uk/pdbe/emdb/).
FIG. 12G is a structure of the hexameric AAA+ molecular
machine ClpC with adaptor protein MecA. (PDB ID: MecAClpC, 3PXG).
FIGS. 13A-13C show a theoretical plot (with variable Z)
and empirical data to illustrate inhibition efficiency with
drug targeting to genomic DNA (Z-1 ).
FIG. 13A is a gel showing the phi29 genome DNA treated
with endonuclease EcoRl.
FIG. 13B is a plot of virion assembly derived from
binomial distribution equation 2, which showed that the
DNA has stoichiometry of 1.

FIG. 13C is a viral assembly inhibition effect of mutant
DNA as model of drugged component with Z=l, showing
the linear relationship to p with low slope.
FIGS. 14A-14C is a theoretical plot (K=l to 6) and
empirical data to illustrate inhibition efficiency with drug
targeting pRNA (Z=6).
FIG. 14A is the sequence and secondary structure of
wild-type pRNA of phi29 DNA packaging motor (upper
panel) and inactive mutant pRNA with 4 bases mutation at
5' end of the DNA translocation domain serving as a model
of drugged inactive pRNA (lower panel).
FIG. 14B is a fitting the phage assembly inhibition result
by inactive mutant pRNA with the theoretical plots derived
from Equation 2 matched with Z=6 and K=l.
FIG. 14C compares the viral assembly inhibition effect by
drugged pRNA at different concentration with the
undrugged pRNA with same dilution factor.
FIGS. lSA-15B shows complete inhibition of viral
assembly in vivo by mutant pRNA as a model of drugged
complex (Z=6).
FIG. 15A shows inactivation of pRNA by introducing a
4-nucleotide mutation at the 3'end.
FIG. 15B shows virion production by wild-type phi29
infection using host cell B. subtilis harboring plasmid
expressing mutant pRNA, wild-type pRNA, or plasmid only.
FIGS. 16A-16C show comparison of inhibition efficiency
using targets with different Z values.
FIG. 16A shows virion production inhibition effect of
mutant gp16 (Z=6) at different concentration.
FIG. 16B shows inhibition efficiency by y-s-ATP with
ATP with high Z value.
FIG.16C compares the virus assembly inhibition effect by
drugged components of DNA, pRNA, gp16 and ATP with
stoichiometry of 1, 6, 6, 10000 respectively.
FIG. 17 shows a relationship between stoichiometry (Z)
and drug targeting level (a combined result of drug binding
efficacy and drug concentration) to reach the inhibition
effect (IC).
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DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The disclosure below includes Section 1 (which includes
the Introduction set forth above and description of FIGS.
1-6), Section 2 (which includes description of FIGS. 7-11 set
forth above), and Section 3 (which includes the description
of FIGS. 12-17 set forth above). Each section discloses
systems, devices, and methods for designing compounds
and compositions as further described below.
Section 1
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
The presently-disclosed subject matter includes a method
for designing a compound or composition for treatment of
virus, bacteria, or cancer having acquired drug resistance,
which involves identifying a multi-subunit bio complex of
the virus or bacteria that is distinct from other biocomplexes
in the subject species, or selecting a multi-subunit bio
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complex of the cancer containing a mutation; and designing
a drug to target subunit of the biocomplex. The present
inventors have surprisingly determined that the inhibitory
efficiency of a drug is related to the stoichiometry of its
targeted biocomplex; the higher the stoichiometry of the
target complex, the more efficient the drug.
This can lead to the development of potent therapeutics
against high-stoichiometric biomachines or biocomplexes as
drug targets. This method was employed as described herein
by using a mutant subunit as the drugged inactive target to
calculate the theoretical inhibition efficiency via binomial
distribution, and compared with experimental data from a
defined in vitro viral assembly system.
The approach in drug development reported here has
general applications especially in developing new generations of drugs for combating the rising acquired drug resistance in viruses, bacteria, and cancers.
Disclosed herein is a method for designing compounds
useful for treating conditions that can be treated by targeting
high stoichiometric complexes, which is useful, for
example, in designing drugs for against in viruses, bacteria,
and cancers having acquired drug resistance.

embodiment, the manmialian subject is administered the
drug identified or designed according to the methods of the
invention.
In one embodiment, methods are provided for increasing
inhibition efficiency of a multimeric biocomplex. In one
embodiment, the method comprises (a) identifying a target
that performs a biological function, wherein the target
comprises one or more subunits, wherein a minimum number of the one or more subunits is inactivated to inhibit the
biological function; (b) selecting a drug that binds specifically to each subunit of the one or more subunits with a
target probability, wherein the target probability comprises a
common probability for each subunit that the drug delivered
to the target inactivates the subunit; (c) describing a relationship between inhibition efficiency of the drug and total
number of the one or more subunits using a binomial
distribution, wherein the inhibition efficiency comprises a
probability that the delivered drug blocks the biological
function, wherein the inhibition efficiency is computed with
respect to the minimum number and the total number; (d)
confirming empirically the relationship using an experimental target, wherein the target includes the experimental
target; and (e) contacting the drug to the target to treat a
multi-drug resistant disease, wherein the target comprises a
biological complex in a manmialian subject. In a further
embodiment, the manmialian subject is administered the
drug identified or designed according to the methods of the
invention.
In one embodiment, methods are provided for optimizing
biocomplex stoichiometry-based drug development. In one
embodiment, the method comprises (a) identifying a target
that performs a biological function, wherein the target
comprises one or more subunits, wherein a minimum number of the one or more subunits is inactivated to inhibit the
biological function; (b) selecting a drug that binds specifically to each subunit of the one or more subunits with a
target probability, wherein the target probability comprises a
common probability for each subunit that the drug delivered
to the target inactivates the subunit; (c) describing a relationship between inhibition efficiency of the drug and total
number of the one or more subunits using a binomial
distribution, wherein the inhibition efficiency comprises a
probability that the delivered drug blocks the biological
function, wherein the inhibition efficiency is computed with
respect to the minimum number and the total number; (d)
confirming empirically the relationship using an experimental target, wherein the target includes the experimental
target; and (e) contacting the drug to the target to treat a
multi-drug resistant disease, wherein the target comprises a
biological complex in a manmialian subject. In a further
embodiment, the manmialian subject is administered the
drug identified or designed according to the methods of the
invention.
In one embodiment, methods are provided for targeting a
high stoichiometry biocomplex to increase drug targeting
efficiency. In one embodiment, the method comprises (a)
identifying a target that performs a biological function,
wherein the target comprises one or more subunits, wherein
a minimum number of the one or more subunits is inactivated to inhibit the biological function; (b) selecting a drug
that binds specifically to each subunit of the one or more
subunits with a target probability, wherein the target probability comprises a common probability for each subunit that
the drug delivered to the target inactivates the subunit; (c)
describing a relationship between inhibition efficiency of the
drug and total number of the one or more subunits using a
binomial distribution, wherein the inhibition efficiency com-

5

10

15

20

25

where Z=stoichiometry, M=drugged subunits in each biocomplex, p and q represent the fraction of drugged and
non-drugged subunits in the population.
Disclosed herein are methods for designing and/or identifying compounds useful for treating conditions that can be
treated by targeting high stoichiometric complexes, which is
useful, for example, in designing and/or identifying drugs
for/against viruses, bacteria, and cancers having acquired
drug resistance. In some embodiments, the compounds
designed or identified herein may be an antibody, an antisense oligonucleotide, miRNA, a short hairpin RNA, a small
peptide, and the like directed to a component or subunit of
the nanomachines (e.g., biomotors or biocomplexes) contemplated herein. Other agents that could be used to bind the
target compound include: protein, aptamer, LNA, chemical
compounds and Polysaccharide.
In one embodiment, methods are provided for the identification of multi-subunit biocomplex drug targets. In one
embodiment, the method comprises (a) identifying a target
that performs a biological function, wherein the target
comprises one or more subunits, wherein a minimum number of the one or more subunits is inactivated to inhibit the
biological function; (b) selecting a drug that binds specifically to each subunit of the one or more subunits with a
target probability, wherein the target probability comprises a
common probability for each subunit that the drug delivered
to the target inactivates the subunit; (c) describing a relationship between inhibition efficiency of the drug and total
number of the one or more subunits using a binomial
distribution, wherein the inhibition efficiency comprises a
probability that the delivered drug blocks the biological
function, wherein the inhibition efficiency is computed with
respect to the minimum number and the total number; (d)
confirming empirically the relationship using an experimental target, wherein the target includes the experimental
target; and (e) contacting the drug to the target to treat a
multi-drug resistant disease, wherein the target comprises a
biological complex in a manmialian subject. In a further
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prises a probability that the delivered drug blocks the
biological function, wherein the inhibition efficiency is
computed with respect to the minimum number and the total
number; (d) confirming empirically the relationship using an
experimental target, wherein the target includes the experimental target; and (e) contacting the drug to the target to
treat a multi-drug resistant disease, wherein the target comprises a biological complex in a mammalian subject. In a
further embodiment, the mammalian subject is administered
the drug identified or designed according to the methods of
the invention.
In one embodiment, methods are provided for treating a
subject afflicted with a multi-drug resistant disease. In one
embodiment, the method comprises: (a) identifying a target
that performs a biological function, wherein the target
comprises one or more subunits, wherein a minimum number of the one or more subunits is inactivated to inhibit the
biological function; (b) selecting a drug that binds specifically to each subunit of the one or more subunits with a
target probability, wherein the target probability comprises a
common probability for each subunit that the drug delivered
to the target inactivates the subunit; (c) describing a relationship between inhibition efficiency of the drug and total
number of the one or more subunits using a binomial
distribution, wherein the inhibition efficiency comprises a
probability that the delivered drug blocks the biological
function, wherein the inhibition efficiency is computed with
respect to the minimum number and the total number; (d)
confirming empirically the relationship using an experimental target, wherein the target includes the experimental
target; and (e) contacting the drug with the target to treat a
multi-drug resistant disease, wherein the target comprises a
biological complex in a mammalian subject. In a further
embodiment, the mammalian subject is administered the
drug identified or designed according to the methods of the
invention.
In some embodiments of the invention, the experimental
target comprises a component or subunit of a multimeric
biocomplex. Non-limiting examples of a multimeric biocomplex include a receptor, a channel, an enzyme, and a
transporter. In other embodiments, the experimental target
comprises a component or subunit of a biological nanomotor. Non-limiting examples of a biological nanomotor
include a linear motor, a rotation motor, and a revolution
motor. In further embodiments, the biological nanomotor
further comprises an ATPase component. In some embodiments, the biological nanomotor is a bacteriophage Phi29
DNA packaging motor. As discussed herein, the bacteriophage Phi29 DNA packaging motor comprises a genomic
dsDNA component, a packaging RNA component, an
ATPase gp 16 component, an ATP component, or a combination thereof.
In one embodiment, the biological motor or multimeric
biocomplex is homomeric. In another embodiment, the
biological motor or the multimeric biocomplex comprises a
dimer, a hetero-oligomer, or a homo-oligomer. In some
embodiments, the number of components or subunits comprising the biological motor or multimeric biocomplex is at
least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90,
or 100. In some embodiments, the number of components or
subunits comprising the biological motor or multimeric
biocomplex is at least 100, 200, 300, 400, 500, 600, 700,
800,900, 1000,2000, 3000, 4000, 5000, 6000, 7000, 8000,
9000, or 10,000. In some embodiments, the number of
components or subunits comprising the biological motor or
multimeric biocomplex is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
or 12. For example, the bacteriophage Phi29 DNA packag-

ing motor comprises 1 copy of genomic dsDNA, and such
copy comprises a subunit (e.g., 1 target subunit). For
example, the bacteriophage Phi29 DNA packaging motor
comprises 6 copies of packaging RNA, and such copies
comprise subunits (e.g., 6 target subunits). For example, the
bacteriophage Phi29 DNA packaging motor comprises 6
copies of gp16, and such copies comprise subunits (e.g., 6
target subunits). For example, the bacteriophage Phi29 DNA
packaging motor comprises 10,000 copies of ATP, and such
copies comprise subunits (e.g., 10.000 target subunits).
As used herein and as is well understood in the art,
"treatment" is an approach for obtaining beneficial or
desired results, including clinical results. Beneficial or
desired clinical results can include, but are not limited to,
alleviation or amelioration of one or more symptoms or
conditions, diminution of extent of disease, a stabilized (i.e.,
not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration
or palliation of the disease state and remission (whether
partial or total), whether detectable or undetectable. "Treatment" can also refer to prolonging survival as compared to
expected survival if not receiving treatment.
The term "in need thereof' refers to the need for symptomatic or asymptomatic relief from a condition associated
with multi-drug resistance, such as, for example, a cancer,
and/or a condition associated with a multi-drug resistant
disease caused by a multidrug-resistant organism. The subject in need thereof may or may not be undergoing treatment
for conditions related to, for example, a cancer, and/or a
condition associated with a multi-drug resistant disease
caused by a multidrug-resistant organism. In some embodiments, the subject is a mammalian subject. In some embodiments, the mammalian subject is a human, a dog, a cat, a
bird, a pig, a horse, or a cow. In certain embodiments, the
mammalian subject is a human.
A multi-drug resistant disease can be caused by a multidrug-resistant organism. The multidrug resistant organism is
no longer responsive to an antibiotic composition treatment,
an antifungal composition treatment, an antiviral composition treatment, or an antiparasitic composition treatment. In
one embodiment, the multidrug-resistant organism is a bacterium, a fungus, a virus, or a parasite. Non-limiting
examples of a multidrug-resistant bacterium include a species of staphylococcus, a species of enterococcus, a species
of gonococcus, a species of streptococcus, a species of
acinetobacter, a species of enterobacter, a species of klebsiella, a species of salmonella, a species of escherichia, a
species of pseudomonas, and a species of mycobacterium.
Non-limiting examples of a multidrug-resistant fungus
include a species of candida and a species of scedosporium.
Non-limiting examples of a multidrug-resistant virus
include HIV, influenza, cytomegalovirus and herpes simplex
virus. Non-limiting examples of a multidrug-resistant parasite include a species of plasmodium, a species of toxoplasma, and a species of ascaris.
The present disclosure relates generally to small molecule
therapeutics useful the treatment of a multi-drug resistant
cancer or a multi-drug resistant disease caused by a multidrug-resistant organism. In one embodiment, a drug identifled or designed according to the methods described herein
is administered to a subject to prevent or treat diseases or
disorders associated with a multi-drug resistant cancer or a
multi-drug resistant disease caused by a multidrug-resistant
organism. In one embodiment, an effective amount of the
drug identified or designed according to the methods
described herein is administered to the subject. In some
embodiments, the drug identified or designed according to
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the methods described herein comprises a pharmaceutical
composition administered to a subject in a pharmaceutically
acceptable carrier. In some embodiments, the drug identified
or designed according to the methods described herein can
serve as a therapeutic method for the treatment of a multidrug resistant cancer or a multi-drug resistant disease caused
by a multidrug-resistant organism.
Embodiments of the invention may be used to treat a
multi-drug resistant cancer or a multi-drug resistant disease
caused by a multidrug-resistant organism Non-limiting
examples of diseases, disorders, and/or illnesses which may
benefit from embodiments of the present invention may
include illnesses caused by Vancomycin-Resistant Enterococci, tuberculosis, pneumonia, illnesses caused by Methicillin-Resistant Staphylococcus aureus, cancer, food poisoning, legionnaire's disease, yeast infections, malaria, and
helminthiasis.
The drug identified or designed according to the methods
described herein can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a
suitable pharmaceutically acceptable diluent or carrier. Use
of the drug compounds and methods of the invention may
also be useful prophylactically.
An "effective amount". "sufficient amount" or "therapeutically effective amount" as used herein is an amount of a
composition that is sufficient to effect beneficial or desired
results, including clinical results. As such, the effective
amount may be sufficient, for example, to reduce or ameliorate the severity and/or duration of an affliction or condition, or one or more symptoms thereof, prevent the
advancement of conditions related to an affliction or condition, prevent the recurrence, development, or onset of one or
more symptoms associated with an affliction or condition, or
enhance or otherwise improve the prophylactic or therapeutic effect(s) of another therapy. An effective amount also
includes the amount of the composition that avoids or
substantially attenuates undesirable side effects.
The term "carrier" refers to a diluent, adjuvant, excipient,
or vehicle with which a compound is administered. Nonlimiting examples of such pharmaceutical carriers include
liquids, such as water and oils, including those of petroleum,
animal, vegetable or synthetic origin, such as peanut oil,
soybean oil, mineral oil, sesame oil and the like. The
pharmaceutical carriers may also be saline, gum acacia,
gelatin, starch paste, talc, keratin, colloidal silica, urea, and
the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. Other examples of
suitable pharmaceutical carriers are described in Remington:
The Science and Practice of Pharmacy, 21st Edition (University of the Sciences in Philadelphia, ed., Lippincott
Williams & Wilkins 2005); and Handbook of Pharmaceutical Excipients, 7th Edition (Raymond Rowe et al., ed.,
Pharmaceutical Press 2012); each hereby incorporated by
reference in its entirety.
The term "pharmaceutically acceptable salts" refers to
physiologically and pharmaceutically acceptable salts of the
compounds of the invention: i.e., salts that retain the desired
biological activity of the parent compound and do not impart
undesired toxicological effects thereto. A pharmaceutically
acceptable carrier can comprise any and all solvents, dispersion media, coatings, antibacterial and antifungal agents,
isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such
media and agents for pharmaceutically active substances is
well known in the art. Any conventional media or agent that
is compatible with the active compound can be used.
Supplementary active compounds can also be incorporated

into the compositions. For oligonucleotide compounds,
examples of pharmaceutically acceptable salts and their uses
are further described in U.S. Pat. No. 6,287,860, which is
hereby incorporated by reference in its entirety.
Embodiments of the present invention can be administered alone, or can be administered in a therapeutic cocktail
or as a pharmaceutical composition. For example, a pharmaceutical composition can comprise embodiments of the
present invention, and a saline solution that includes a
phosphate buffer. Embodiments of the present invention can
be administered using the means and doses described herein.
Embodiments of the present invention can be administered
in combination with a suitable carrier. In one embodiment,
the drug identified or designed according to the methods
described herein encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other
compound which, upon administration to a subject, provides
(directly or indirectly) the biologically active metabolite or
residue thereof.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, (e.g., intravenous), intradermal, subcutaneous, oral
(e.g., inhalation), transdermal (topical), transmucosal, and
rectal administration. Solutions or suspensions used for
parenteral, intradermal, or subcutaneous application can
include the following components: a sterile diluent such as
water for injection, saline solution, fixed oils, polyethylene
glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl
parabens; antioxidants such as ascorbic acid or sodium
bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates
and agents for the adjustment of tonicity such as sodium
chloride or dextrose. pH can be adjusted with acids or bases,
such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable
syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use
include sterile aqueous solutions (where water soluble) or
dispersions and sterile powders for the extemporaneous
preparation of sterile injectable solutions or dispersions. For
intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EM™
(BASF, Parsippany. N.J.) or phosphate buffered saline
(PBS). In all cases, the composition must be sterile and
should be fluid to the extent that easy syringability exists. It
must be stable under the conditions of manufacture and
storage and must be preserved against the contaminating
action of microorganisms such as bacteria and fungi. The
carrier can be a solvent or dispersion medium containing, for
example, water, ethanol, a pharmaceutically acceptable
polyol like glycerol, propylene glycol, liquid polyetheylene
glycol, and suitable mixtures thereof. The proper fluidity can
be maintained, for example, by the use of a coating such as
lecithin, by the maintenance of the required particle size in
the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by
various antibacterial and antifungal agents, for example,
parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it can be useful to include isotonic
agents, for example, sugars, polyalcohols such as mannitol,
sorbitol, sodium chloride in the composition. Prolonged
absorption of the injectable compositions can be brought
about by including in the composition an agent which delays
absorption, for example, aluminum monostearate and gelatin.
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Sterile injectable solutions can be prepared by incorporating the compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated herein, as required, followed by filtered
sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which
contains a basic dispersion medium and the required other
ingredients from those enumerated herein. In the case of
sterile powders for the preparation of sterile injectable
solutions, examples of useful preparation methods are
vacuum drying and freeze-drying which yields a powder of
the active ingredient plus any additional desired ingredient
from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an
edible carrier. They can be enclosed in gelatin capsules or
compressed into tablets. For the purpose of oral therapeutic
administration, the active compound can be incorporated
with excipients and used in the form of tablets, troches, or
capsules. Oral compositions can also be prepared using a
fluid carrier for use as a mouthwash, wherein the compound
in the fluid carrier is applied orally and swished and expectorated or swallowed.
Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain
any of the following ingredients, or compounds of a similar
nature: a binder such as microcrystalline cellulose, gum
tragacanth or gelatin; an excipient such as starch or Lactose,
a disintegrating agent such as alginic acid, Primogel, or corn
starch; a lubricant such as magnesium stearate or sterotes; a
glidant such as colloidal silicon dioxide; a sweetening agent
such as sucrose or saccharin; or a flavoring agent such as
peppermint, methyl salicylate, or orange flavoring.
Systemic administration can also be by transmucosal or
transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the harrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for
transmucosal administration, detergents, bile salts, and
fusidic acid derivatives. Transmucosal administration can be
accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds
are formulated into ointments, salves, gels, or creams as
generally known in the art.
Formulations useful for topical administration include
those in which the drug identified or designed according to
the methods described herein are in admixture with a topical
delivery agent such as lipids, liposomes, fatty acids, fatty
acid esters, steroids, chelating agents and surfactants. Exemplary lipids and liposomes include neutral (e.g. diolcoylphosphatidyl ethanolamine (DOPE), dimyristoylphosphatidyl choline (DMPC), distearolyphosphatidyl choline)
negative (e.g. dimyristoylphosphatidyl glycerol (DMPG))
and cationic (e.g. diolcoyltetramethyl-aminopropyl (DOTAP), and diolcoyl-phosphatidyl ethanolamine (DOTMA)).
For topical or other administration, the drug identified or
designed according to the methods described herein can be
encapsulated within liposomes or can form complexes
thereto, in particular to cationic liposomes. Alternatively, the
drug identified or designed according to the methods
described herein can be complexed to lipids, in particular to
cationic lipids. Exemplary fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further
described in U.S. Pat. No. 6,287,860, which is hereby
incorporated by reference in its entirety.
The formulation of therapeutic compositions and their
subsequent administration (dosing) is believed to be within

the skill of those in the art. Dosing is dependent on severity
and responsiveness of the disease state to be treated, with the
course of treatment lasting from several days to several
months, or until a cure is effected or a diminution of the
disease state is achieved. Optimal dosing schedules can be
calculated from measurements of drug accumulation in the
body of the patient. Persons of ordinary skill can easily
determine optimum dosages, dosing methodologies and
repetition rates. Optimum dosages may vary depending on
the relative potency of the drug identified or designed
according to the methods described herein, and can generally be estimated based on EC50s found to be effective in in
vitro and in vivo animal models. In some embodiments, the
therapeutically effective amount is at least about 0.1 mg/kg
body weight, at least about 0.25 mg/kg body weight, at least
about 0.5 mg/kg body weight, at least about 0.75 mg/kg
body weight, at least about 1 mg/kg body weight, at least
about 2 mg/kg body weight, at least about 3 mg/kg body
weight, at least about 4 mg/kg body weight, at least about 5
mg/kg body weight, at least about 6 mg/kg body weight, at
least about 7 mg/kg body weight, at least about 8 mg/kg
body weight, at least about 9 mg/kg body weight, at least
about 10 mg/kg body weight, at least about 15 mg/kg body
weight, at least about 20 mg/kg body weight, at least about
25 mg/kg body weight, at least about 30 mg/kg body weight,
at least about 40 mg/kg body weight, at least about 50 mg/kg
body weight, at least about 75 mg/kg body weight, at least
about 100 mg/kg body weight, at least about 200 mg/kg
body weight, at least about 250 mg/kg body weight, at least
about 300 mg/kg body weight, at least about 350 mg/kg
body weight, at least about 400 mg/kg body weight, at least
about 450 mg/kg body weight, or at least about 500 mg/kg
body weight.
In one embodiment, the drug identified or designed
according to the methods described herein can be administered to the subject one time (e.g., as a single injection or
deposition). Alternatively, administration can be once or
twice daily to a subject in need thereof for a period of from
about 2 to about 28 days, or from about 7 to about 10 days,
or from about 7 to about 15 days. It can also be administered
once or twice daily to a subject for a period of 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12 times per year, or a combination thereof.
For example, the dosage may be given once or more daily,
weekly, monthly or yearly, or even once every 2 to 20 years.
In one embodiment, two or more combined the drug identified or designed according to the methods described herein,
therapeutics, and the like may be used together in combination or sequentially. The dosage can vary depending upon
known factors such as the pharmacodynamic characteristics
of the active ingredient and its mode and route of administration; time of administration of active ingredient; age, sex,
health and weight of the recipient; nature and extent of
symptoms; kind of concurrent treatment, frequency of treatment and the effect desired; and rate of excretion. Persons of
ordinary skill in the art can easily estimate repetition rates
for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following
successful treatment, it may be desirable to have the patient
undergo maintenance therapy to prevent the recurrence of
the disease state, wherein the drug identified or designed
according to the methods described herein is administered in
maintenance doses, ranging from at least about 0.1 mg/kg
body weight to about 10 mg/kg of body weight, from at least
about 0.1 mg/kg body weight to about 20 mg/kg of body
weight, from at least about 0.1 mg/kg body weight to about
30 mg/kg of body weight, from at least about 0.1 mg/kg
body weight to about 40 mg/kg of body weight, from at least
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about 0.1 mg/kg body weight to about 50 mg/kg of body
weight, from at least about 0.1 mg/kg body weight to about
60 mg/kg of body weight, from at least about 0.1 mg/kg
body weight to about 70 mg/kg of body weight, from at least
about 0.1 mg/kg body weight to about 80 mg/kg of body
weight, from at least about 0.1 mg/kg body weight to about
90 mg/kg of body weight, from at least about 0.1 mg/kg
body weight to about 100 mg/kg of body weight, once or
more daily, to once every 2-20 years.
While the terms used herein are believed to be well
understood by those of ordinary skill in the art, certain
definitions are set forth to facilitate explanation of the
presently-disclosed subject matter. Unless defined otherwise, all technical and scientific terms used herein have the
same meaning as commonly understood by one of ordinary
skill in the art to which the presently-disclosed subject
matter belongs.
Although any methods, devices, and materials similar or
equivalent to those described herein can be used in the
practice or testing of the presently-disclosed subject matter,
representative methods, devices, and materials are now
described.
In certain instances, nucleotides and polypeptides disclosed herein are included in publicly-available databases,
such as GENBANK® and SWISSPROT. Information
including sequences and other information related to such
nucleotides and polypeptides included in such publiclyavailable databases are expressly incorporated by reference.
Unless otherwise indicated or apparent the references to
such publicly-available databases are references to the most
recent version of the database as of the filing date of this
Application.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as is commonly
understood by one of skill in the art to which the invention(s)
belong. All patents, patent applications, published applications and publications, GenBank sequences, databases, websites and other published materials referred to throughout the
entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there
are a plurality of definitions for terms herein, those in this
section prevail. Where reference is made to a URL or other
such identifier or address, it understood that such identifiers
can change and particular information on the internet can
come and go, but equivalent information can be found by
searching the internet. Reference thereto evidences the
availability and public dissemination of such information.
Following long-standing patent law convention, the terms
"a", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodi-

ments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method.
The terms "animal," "subject," and "patient" as used
herein includes all members of the animal kingdom including, but not limited to, mammals, animals (e.g., cats, dogs,
horses, swine, etc.) and humans.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the present invention.
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Materials and Methods
Preparation of Mutant Genomic dsDNA
Phi29 genomic DNA-gp3 was purified from B. subtilis
SpoA12 cells by CsCl gradient ultracentrifugation as
described previously [63]. Mutant dsDNA was prepared by
digesting the phi29 genomic dsDNA with EcoRl restriction
enzyme in fast digest buffer (Fermentas) at 37° C. for 1 hour
followed by ethanol precipitation. The mutant DNA was
tested by 1% agarose gel electrophoresis, stained by
ethidium bromide (Sigma) and imaged by Typhoon (GE).
Preparation of Mutant pRNA
Wild-type phi29 pRNA and inactive mutant as drugged
pRNA were prepared by in vitro transcription. In the inactive
mutant pRNA, the first four bases "UUCA" (SEQ ID NO: 1)
located at the 5' end were mutated to "GGGG" (SEQ ID NO:
2). Bg!II digested plasmid pRT71 was used as DNA template
[64] in the PCR reaction for both RNAs. Oligonucleotide
5'-TAA TAC GAC TCA CTA TAG GGG TGG TAC-3' (SEQ
ID NO: 3) and 5'-TTA TCAAAG TAG CGT GCA C-3'(SEQ
ID NO: 4) were used as primers for mutant pRNA. RNAs
were then transcribed by T7 RNA polymerase using doublestranded DNA generated from PCR, as described before
[65]. The RNA from in vitro transcription was further
purified by 8 M urea 8% polyacrylamide gel electrophoresis
as described previously [64].
Preparation of Mutant ATPase Gp16
The purification of wild-type gp16 has been described
previously [63]. The walker B mutant gp16 was constructed
by introducing mutations in the gp16 gene. The amino acid
residues D255 and E256 in walker B motif of gp16 were
mutated to E255 and D256, respectively. The mutation was
introduced with the Stratagene Quick Change site-directed
mutagenesis kit using appropriate primers. The expression
and purification of protein were carried out followed a
published procedure [51].
Antisense Oligonucleotides
Antisense oligonucleotides P3 and P15 were designed to
be reversely complementary to different regions on the
pRNA molecule and chemically synthesized by IDT. P3
oligo (5'-TTGCCATGATTGACAAC-3' (SEQ ID NO: 5))
targets the region of 83-99 nucleotides at the 3'end of pRNA,
P15 oligo (5'-AAGTACCGTACCATTGA-3' (SEQ ID NO:

US 10,975,412 B2
17

18

6)) targets the region of 1-17 nucleotides at the 5'end of
pRNA.
PS
oligo
(5'-TAATACGACTCACTATAGGGGTGGTAC-3 (SEQ ID NO: 7)) was designed as
a non-targeting control in the test. 1 µI of individual oligos
at 100 µM were mixed with 1 µI of pRNA at 4 µM and
dialyzed on a 0.025 µm mixed cellulose esters VSWP filter
membrane (Millipore Corp) against TBE buffer (89 mM
Tris-HCI, pH 8.3, 89 mM boric acid, 2.5 mM EDTA) at
room temperature for 15 min. The purified RNA complex
was used for in vitro phi29 assembly assay.
In Vitro Phi29 Assembly Assay
Purified components were subjected to in vitro viral
assembly assay as described previously [66]. Briefly, 10 µg
of purified procapsids were mixed with 100 ng of pRNA in
5 µI ofreaction buffer (10 mM ATP, 6 mM 2-mercaptoethano!, and 3 mM spermidine in TMS buffer) at room temperature for 30 min. Purified DNA-gp3 and gp16 were then
added and the reaction mixture was incubated at room
temperature for one hour to initiate DNA packaging. Finally,
the DNA filled procapsids were incubated with 10 µI of
gpS.5-9 extract from E. coli containing plasmid pARgpS.5-9
and 20 µI of gpll-14 extract from E. coli to complete the
infectious phage assembly.
The newly assembled infectious viruses were plated with
inoculated B. subtilis bacteria su+44 cells onto a half LB
plate covered with top agar. After 12 hour incubation at 37°
C., the viral assembly efficiency (plaque-forming unit, PFU)
was calculated by counting the formed plaque numbers.
Mixing different ratios of mutant with wild-type components, while keeping all other components the same, the
viral assembly efficiency (PFU) versus ratio of mutant
components gave an empirical curve for vial assembly
inhibition assay, and it was compared with theoretical curves
from the binomial distribution equation.
In Viva Viral Assembly Assay
Plasmid pRBwtRNA containing the pRNA coding
sequence under T7 promoter was constructed by ligating the
fragment coding pRNA sequence and T7 promoter into
pRB381-L550 vector (modified and kindly provided by M.
Wang and H Zalkin) following a previously described
method [67]. Plasmid pRBmutRNA contained mutant
pRNA under its natural promoter PEI sequence, and the
mutation was changing sequence 5'UUGA-3' (SEQ ID NO:
8) at its 3'end to 5'GGGG-3' (SEQ ID NO: 9). The DNA
fragments coding mutant pRNA sequence and PEI sequence
were prepared by PCR as described previously[ 67]; and
digested with HindIII-Bg!II restriction enzyme. The mutant
pRNA sequence coding fragment was further ligated with a
6.0 kb fragment from pRB381-L550 that was digested with
HindIII and partially digested with Bg!II.
The plasmids pRBmutRNA, pRBwtRNA, and pRB381L550 were transformed into B. subtilis cells following
methods described previously [67]. The B. subtilis cells
harboring transformed plasmids were incubated in 416
medium with 10 mg/ml of neomycin for 3 hours at 3 7° C.
and then plated onto LB-neomycin (10 mg/ml) plates for
plaque formation analysis.
Results
The Definition of "Stoichiometry".
The definition of the stoichiometry in this report is
different from conventional definition of stoichiometry used
to evaluate drug efficiency. Conventionally the concept of
stoichiometry refers to the number of a drug binding to each
target molecule, which is also known as Bmax· In this study
the definition of stoichiometry refers to the copy number of
subunit within a biocomplex or the nanomachine that serves
as drug target.

The Definition of "K Value", and K=l is One Key for
Ultra-High Inhibition Efficacy
Suppose a biocomplex drug target contains Z copies of
subunits, then K is the copy number (KsZ) of drugged
subunits required to inhibit the function of the complex or
the nanomachine. As an analogy to the difference between
the parallel circuit and the serial circuit, when the Christmas
lights are arranged in a parallel circuit, any light bulbs that
are burnt out will not affect other bulbs. But in a serial
circuit, any one light bulb that is broken will stop the entire
lighting system, which is K=l. Thus, the K value is the key
to the probability of inactive nanomachines or biocomplexes
by combination and permutation of all subunits. K equals 1
is critical for such ultra-high inhibition effect. The foundation of the approach in this report is the difference in
probability of inhibited biocomplexes in systems of different
K values with combination and permutation algorithms.
Biological systems display complicated reactions. Many
reactions involve multiple subunits to work cooperatively
sequentially or processively to accomplish one essential
biological function [33,68,69, 70, 71, 72, 73, 7 4, 75]. Single
assembly pathways have been reported in the viral assembly
system [7 6, 77]. In most cases of the sequential, cooperative,
and processive action, inactivation of any one, not necessary
all, of the subunits will result in inhibition of its function,
thus K=l. Drug synergism was utilized in multi-target drug
therapy; in short, a drug combination can simultaneously act
on multiple targets in disease networks to produce a synergistic effect [50,78]. However, our design reported here is
unique from the conventional synergistic approach. We
suggest that using multi-subunit biocomplexes as drug target
could lead to development of ultra-high potent drugs. In a
conventional six-component system, for example one drug
is designed to target component #3 to stop the entire system,
since the drug can only target component #3, the condition
fits the model of Z=l and K=l. Thus, the inhibition efficiency and substrate targeting efficiency (p) of drug will be
in linear relationship. However, in the system in this report,
the entire system will be blocked when drug targets any
subunit of a hexamer, which is Z=6 and K=l. Thus the
probability of remaining undrugged targets will be q 6 , where
q represents the fraction of untargeted hexamer subunits; in
other words, the drug inhibition efficiency will be l-q6 ,
which increases following a power function compared to the
linear for conventional mono-subunit approaches.
Assuming that at least K copies of drugged subunits were
needed to deactivate the nanomachine or biocomplex, the
probability of functional biocomplexes in the presence of
various ratios of inhibited and wild-type subunits could be
predicted from equation 2. When K=l, it implies that drug
binding to one subunit will inactivate the subunit, and one
drugged subunit per multi-subunit complex is sufficient to
inhibit the overall function of the complex. The inhibition
efficiency by drugs targeting multi-subunit biocomplexes
with stoichiometry of Z will equal l-q as shown in table
2. An example for such a probability calculation when Z=6
and K=l is as follows: since it was assumed that 6 (Z=6)
copies of subunits per element were required for function
and one drugged subunit (K=l) was sufficient to block its
activity, all elements possessing 1 to 5 copies of drugged
subunits would be non-functional (FIG. lC). Only those
complexes possessing 6 copies of normal subunits will be
functional. The chance for a complex containing 6 copies of
unaffected subunits in a population is q 6 and the inhibition
efficiency will be l-q 6 •
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Rationale Behind Selection of Multi-Subunit Biocomplexes as Efficient Drug Targets
Mechanisms for drug inhibition of organism growth are to
block or stop an essential biological element from functioning. When a drug is designed to target the subunit of a
complex with targeting efficiency p, a fraction of subunits
will not interact with the drug (a percentile given as g,
p+q=l) and will remain active and exert their functi_on
properly. Some biological elements are monomers contaming only one subunit, while other biological elements, such
as the bio-motors of hexameric AAA+ family, consist of
multiple-subunits [19,34]. Conventional drugs are designed
to inhibit pathogenesis through targeting of a single subunit
molecule, such as an enzyme or a structural protein of a
virus. In this situation, the inhibition efficiency is proportional to the substrate targeting efficiency p and the effect is
proportional to the first order of p. As described above, in
most cases of sequential action or cooperatives in multiple
subunit complexes, inactivation of one, not all, of the
subunits will result in inhibition of its function. Thus, if
complexes containing Z copies of subunits exercise their
function in a sequential and cooperative way, then K=l, and
the fraction of the uninhibited active biocomplex will be q
a higher order with regards to the stoichiometry. The inhibition proportion will equal l-q2 .
In this investigation, a well-defined in vitro phi29 viral
assembly system was used to represent a multi-subunit
nano-machine target, with the mutant component representing a target component that have been inactivated by. an
effective drug. Then, the inhibition efficiencies by targetmg
different elements of the phi29 DNA packaging motor with
different stoichiometry were compared. The viral assembly
competition assays combined with binomial distribution
analysis illustrated the concept that drug targeting functional
biological complexes of a higher-stoichiometry has a higher
efficiency than drug acting on a single subunit target.
When the target element is a monomer containing only
one subunit, the inhibition efficiency can be calculated
through a binomial distribution (equation 1), where p and q
are the fractions of drugged (substrate targeting efficiency)
and undrugged (normal active elements) subunits, respectively (p+q=l).

Computational results based on the binomial equation are set
forth herein. The context of the results governs which form
of the equation is used.
For example, if Z is 3, the probability of all combinations
of drugged subunits (M) and undrugged subunits (N;
M+N=Z) in a given biocomplex entity can be determined by
. o f equat10n
. 2 : (p +q)3 =p 3 +3p 2 q+ 3pq2 +q3_1
the expans10n
- .
That is, the probability of a complex element possessing
three copies of drugged subunits in the population isp 3 , two
copies of drugged and one copy of undrugged or wild-type
subunit is 3p 2 q, one copy of drugged and two copies of
undrugged subunits is 3pq2 , and three copies of undrugged
subunits is q3 • Assuming there were 70% (p=0.7) of subunits
inactivated by bound drugs, and 30% (q=0.3) unaffected
subunits in the population, then the percentage of elements
possessing at least two copies of normal subunits would be
the sum of those possessing one copy of drugged and two
copies of undrugged wild-type subunits, 3pq2 , and those
possessing three copies of native subunits is q 3 • That is
3pq2 +q3 =3(0. 7)(0.3 )2 +(0.3 )3=0.216=21.6%. In another
example, if one complex contains 6 subunits, and 5 out of
the 6 subunits need to remain uninhibited in order to be
biologically functional, the active complex ratio in the
population will be the sum of: 1) the probability of each
element containing 5 undrugged subunits, and 2) the probability of each element containing 6 undrugged subunits.
The probability X in the population displaying a certain
combination of undrugged versus drugged subunits can be
predicted by a binomial distribution, as shown in equat~on 2.
Table 1 shows the probability of a given element with M
drugged and N undrugged subunits at increasing percentages
of drugged subunits in the population, considering that the
total subunits in one element (Z) is 3 or 12. The formula,
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However, when the target element contains multiple subunits, a high order binomial distribution (equation 2) is
applied to calculate the drug inhibition effect by finding the
ratio of resulted active and inactive complexes, where Z
represents the total number of subunits (the stoichiometry)
in one biocomplex and M represents the number of drugged
subunits in one biocomplex.

X = (p+q)

,

~
=U

25

30

35

Z!
M N
M!N!p q

40

45

50

(2)

f (

( Z) Z-M M _
Z!
) Z-M M
M p
q - ~o M!(Z-M)! p
q

55

M=O

Note that the binomial distribution as set forth in equation
2 may also be expressed as follows:

z
I
M=O

Z

M

Z-M

(M )p q

z

ZI

.

= I(M!(Z-M)!
M=O

)

M

60

-M

p q2

65

(from equation 2) was used to calculate each combination
probability value, the coefficient

Z!
M!N!

in this equation can also be calculated using Yang Hui
Triangle, which is also called Pascal's Triangle, or binomial
distribution (FIG. 18)[79].
In Vitro Virus Assembly System Used for Testing the
Hypothesis
The highly sensitive in vitro phi29 assembly system was
used to determine the inhibition efficiency of drugs targeting
multi-subunit complexes [56,66,76,80]. Bacteriophage
phi29 DNA packaging motor contains one copy of genomic
dsDNA, 6 copies of packaging RNA, 6 copies of ATPase
protein gp16 and more than 10000 copies of ATP. The
stoichiometry of RNA in phi29 has been proven by extensive studies including single-molecule studies[81] AFM
images (FIG. lD) [82,83], pRNA crystal structure determination (FIG. lE) [84], and mathematical studies [56]. The
stoichiometry of gpl 6 in phi29 has been proven by multiple
approaches including native gel binding, capillary electrophoresis assays, Hill constant determination, and by titration
of mutant subunits using binomial distribution [19,33].
Many other AAA+ superfamily members have been found to
be hexamers as well [85,86,87,88,89,90,91], such as a red
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type rubisco activase AAA+ protein CbbX (FIG. lF) [85],
MecA-ClpC molecular machine (FIG. 1G)[86]. The copy
number of ATP molecules was calculated based on the fact
that 6 ATP molecules are required to package one pitch of
dsDNA with 10.5 basepairs (bp) [92], thus 1 ATP is used to
package 1.7 bp. The entire phi29 genome is composed of
19.4 kbp, thus, it is expected that more than 10000 ATP
molecules are required to package the entire phi29 genome.
The phi29 DNA nano-motor which packages an entire
genomic DNA into the procapsid can be treated as a disease
model for drug inhibition efficiency analysis.
In Vitro Testing of the Hypothesis Using DNA Element
with Stoichiometry of 1
The inhibition efficiency of drugs targeting a single subunit substrate was tested by in vitro phi29 assembly inhibition by mutating the genomic dsDNA (FIG. 2A). Various
ratios of mutant DNA were mixed with wild-type DNA in in
vitro viral assembly assays. The empirical curve of viral
assembly efficiency against drugged mutant DNA ratio fits
well with the theoretical curve from binomial distribution
for Z=l and K=l (FIG. 2B). This suggests that when
designing drug targeting the genomic DNA in phi29 nanomotor, it is expected to be a first order inhibition response.
Comparing the in vitro phi29 assembly inhibition, by adding
drugged mutant DNA, with simply diluting wild-type DNA
concentration as a control, revealed that the drugged mutant
DNA didn't cause much difference (FIG. 2C). The results
showed that the inhibition effect of drugs targeting the
substrate with stoichiometry of 1 is minimal.
In Vitro Testing of the Hypothesis Using RNA Elements
with Stoichiometry of 6
The pRNA of phi29 contains two domains; a head-loop
domain essential for procapsid binding and a helix domain
essential for DNA translocation (FIG. 3A, upper panel)
[30,93,94]. The right-hand loop and left-hand loop of two
pairing pRNA molecules can interact with each other by
complementary base pairing. Extensive studies have led to
the conclusion that 6 copies of pRNA form a hexameric ring
which binds to the procapsid for virus activity [81,82,83,84].
Drugged mutant pRNA was constructed by mutating 4
nucleotide sequences at the 5'end region of pRNA (FIG. 3A,
lower panel), which has been shown to compete with
wild-type pRNA for procapsid binding, hut was found to be
deficient in allowing DNA packaging to occur [67]. The
theoretical curves generated using the expansion of binomial
distribution equation while total subunit number Z is 6 and
varying K number from 1 to 6 are shown in FIG. 3B. Fitting
the empirical data from phage assembly efficiency at different ratios of drugged mutant pRNAs into the theoretical
curves, the empirical data fit into the theoretical curve of
Z=6 and K=l. It suggested that the pRNA oligomer ring is
composed of six copies of pRNA subunits and one subunit
of the pRNA multimer blockage is sufficient to block the
phage assembly activity. Comparing the empirical curve for
viral assembly efficiency against different ratios of drugged
mutant pRNAs with the wild-type pRNA concentration
dilution control, addition of drugged mutant pRNA showed
a much stronger inhibition effect (FIG. 3C).
To further prove the concept that drugs targeting biocomplex with high stoichiometry causes stronger inhibition
effect, antisense oligonucleotides which can bind to pRNA
molecules were designed as mock drugs in the viral assembly assay. The oligonucleotides P15, and P3 were designed
to target the 5'-end and 3'-end regions on pRNA, respectively. It was confirmed that the antisense oligonucleotides
can be hybridized to pRNA by gel shift assay (data not
shown). When mixing the antisense oligonucleotides with

wild-type pRNA for in vitro phi29 assembly assay, complete
inhibition effects were shown by antisense oligonucleotides
P15, and P3, but not with the non-targeting control oligonucleotide P8[95]. By mixing the non-targeting oligo PS
with pRNA, it generated plaques with 4.4xl0 6 PFU on the
plate.
In Vivo Testing of the Hypothesis Using RNA Elements
with Stoichiometry of 6
Formation of the hexameric ring of pRNA in the phi29
dsDNA packaging motor has been discovered through biochemical and structural studies [52,81,84,96,97,98,99,100,
101,102,103] and activity assays [94,104]. The observed
high inhibition efficiency by drugged mutant pRNA on
phi29 assembly in vitro was striking [67,105]. To test
whether such a high level of inhibition was attainable in
vivo, pRBmutRNA plasmid expressing a pRNA with 4-base
mutation at the 3' end (FIG. 4A) was transformed into B.
subtilis DEi cells. Plasmid pRBwtRNA contained the
pRNA coding sequence but do not express pRNA in B.
subtilis DEi cells, and vector pRB381-L550 was introduced
as well as a negative control. The results showed that only
cells harboring pRBmutRNA plasmid were completely
resistant to plaque formation by wild-type phi29 virus
infection. Control cells, includingB. subtilis 12Acells alone,
B. subtilis DEi cells carrying vector pRB381-L550 alone,
and cells carrying a wild-type pRNA coding sequence but no
expression plasmid pRBwtRNA were all positive for plaque
formation (FIG. 4B). The ability of mutant pRNAs generated in cells by plasmid pRBmutRNA completely inhibited
plaque formation indicated that hexameric pRNA in DNA
packaging nano-motor may be a potential target for developing potent antiviral agents [67].
In Vitro Testing of the Hypothesis Using theATPase with
Stoichiometry of 6
Hexameric folding of ATPase gp16 protein in the phi29
dsDNA packaging motor has been discovered [1,19,33,35].
The hexameric gp16 protein complex functions as ATPase
like many other AAA+ superfamily members. ATP binding
to one subunit of gp16 stimulates the ATPase to change its
conformation from having a lower affinity to one having a
higher affinity for dsDNA.
Determination of gp 16 stoichiometry was carried out by
in vitro phage assembly assay and based on the binomial
distribution of wild-type and Walker B mutant gp16 [51].
Different ratios of drugged Walker B mutant gp16 were
mixed with undrugged gp16 to test the inhibition efficiency
of gp16 mutation on phi29 DNA packaging motor. Assuming K equals 1 and the total copy number of gp16 (Z) is
between 1 and 12, twelve theoretical curves for the production of phi29 virion against the ratio of the Walker B mutant
corresponding to the stoichiometry (Z) of 1 to 12 were
generated according to equation 2. The empirical data nearly
perfectly overlapped the theoretical curve of Z=6, K=1[51].
This data suggested that the ATPase gp16 components of
phi29 DNA packaging motor have a stoichiometry of six,
and only one copy of the drugged gp16 can block the phi29
motor function. Comparing the inhibition effect of adding
mutant gp16 with wild-type gp16 at different concentrations,
it showed that adding mutant gp16 had a much stronger
inhibition effect than the wild-type gp16 concentration dilution control (FIG. SA). Comparing the inhibition effect of
mutation on hexameric gp16 to the effect of mutation on
single subunit target DNA, the gp16 mutation displayed a
much stronger inhibition effect on virus assembly than the
same ratio of DNA mutation, indicating the hexameric
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ATPase protein complex of virus assembly system should
also be an efficient target for generating new anti-virus drugs
with high potency.
In Vitro Testing of the Hypothesis Using ATP with Stoichiometry of More than 10000
It has been reported that 6 ATP molecules are required to
package one pitch of dsDNA with 10.5 bp [90], thus 1 ATP
is used to package 1.7 bp. As the entire phi29 genomic DNA
has 19,000 base pairs, it is expected that more than 10000
ATP molecules are required to package the entire phi29
genome. Since concerning ATP, the functional unit displayed
in FIG.Sis the viral production expressed as plaque-forming
unit (PFU), so the production of one functional unit of PFU
require 10000 ATP subunits to package one genomic DNA.
Thus, the ATP in one phi29 nanomotor can be regarded as a
stoichiometry of 10000. One non-hydrolysable ATP analogue y-S-ATP was treated as the drugged subunit that mixed
with ATP at different ratios to test the inhibition effect of
y-S-ATP on phi29 assembly efficiency. It was found that the
inhibition curve of mutant ATP fits into the theoretical curve
between Z=l00. K=l and Z=60. K=l (FIG. SB). The empirical ATP value derived from binomial distribution assay was
different from real condition, since the binomial distribution
equation was based on a condition that each subunits has the
same binding affinity to the biocomplex in the targeted
nanomotor, but due to the change of the y-S-ATP structure,
it has a ATPase gp 16 binding affinity lower than the normal
ATP. Furthermore, the affinity difference in each subunit has
a multiplicative effect in the nanomotor's activity. Thus,
there is a big discrepancy between the curves with predicted
Z value and the empirical Z value.
Comparing virus assembly inhibition effect using different components, the y-S-ATP showed a severe inhibition
effect (FIG. SC). Adding 20% of gamma-s-ATP nearly
completely inhibited the viral assembly. Comparing the
inhibition effect targeting to ATP, pRNA, ATPase gpl 6, and
DNA with stoichiometry of 10000, 6, 6, and 1, respectively,
y-S-ATP showed the strongest inhibition effect, while
drugged mutant pRNA and mutant gp16 showed stronger
inhibitory effect than mutant DNA (FIG. SC). For example,
adding 20% mutant DNA caused 20% inhibition effect in
viral assembly, while 20% of drugged mutant pRNA exerted
74% of inhibition effect on viral assembly and 20% of
y-S-ATP almost completely inhibited the viral assembly,
indicating the higher the stoichiometry, the stronger the
inhibition efficacy.
Mathematical Reasoning for the Increase of Inhibition
Efficacy
Using a biological complex with higher stoichiometry as
drug target will substantially reduce the proportion of noninhibited complex. For K=l, the proportion of non-inhibited
complex is q2 . Table 3 compares the proportion of noninhibited complex from two populations with Z=6 and Z=l,
respectively, with varied substrate targeting efficiency (p)
when K=l. For example, when q=0.4, the proportion of
non-inhibited complex is q2 =0.4 1 =0.4 for Z=l. K=l. Therefore, only 1-0.4=60% of complex is inhibited. In contrast,
for Z=6, K=l, the proportion of non-inhibited complex is
q2 =0.4 6=0.0041. Therefore, 1-0.0041=99.59% of complex
is inhibited. The ratio of the proportions of non-inhibited
complex
equals
0.0041/0.4=0.0102,
indicating
a
1/0.0102=98-fold decrease in the proportion of non-inhibited complex. One more example is to use the drug targeting
efficiency p=0.9 to compare the inhibition efficiency
between two groups with Z=6 and Z=l. For Z=6, K=l, the
proportion of inhibited complex is l-q2 =1-0.l 6=0.999999.
The proportion of non-inhibited complex is q2 =0.l 6=1E-6.

For Z=l, K=l, the proportion of inhibited complex is
l-q2 =1-0.1=0.9. The proportion of non-inhibited complex
is q2 =0.1. The ratio of inhibition efficiency equals to lE-6/
0.l=lE-5, indicating a 10000-fold increase in inhibition
efficiency (Table 3 ).
The equation displays inhibitory effect with a power
function of stoichiometry since when K = 1, the percentage of
uninhibited biocomplexes in the population equal to q
Since (P+q)=l, thus qsl, thus the larger the Z, the smaller
the value of q That is to say, the higher the stoichiometry,
the smaller number of the uninhibited background will
display. With the same substrate targeting efficacy, p, the
inhibition efficiency is determined by z, the power of the
equation component. The inhibitory effect is a power function concerning the stoichiometry. Thus, the higher the
stoichiometry, the more efficient the inhibition comparing
the drugs with same binding affinity.
The half maximal inhibitory concentration (IC 50 ) is commonly used to evaluate drug effect, which quantitatively
indicates how much of a particular drug is needed to inhibit
a given biological process by half. Ifwe denote Picso as the
percentage of drugged subunit needed to reach to 50%
inhibition in the in vitro assay in the defined system, thus
l-(1-Picsof=50%. Solving this equation, Picso=l-0.5 112.
FIG. 6 shows the relationship between stoichiometry (Z) and
drug targeting level p to reach the inhibition effect (IC),
where p is the combined result of drug binding efficacy and
drug concentration (dosage). When biocomplexes with stoichiometry of Z are used as drug targets, the dosage of drug
or the drug binding affinity presented by percentage of
drugged subunits to reach IC 50 , IC 25 , or IC 75 decreases. This
clearly shows that as Z increases, decreases (FIG. 6), and
hence the drug is more potent.
Discussion
Aiming to find a method for developing drugs with
ultra-high potency, we proposed that the inhibition efficiency of a given drug depends on stoichiometry of the
biocomplex or bio-machine that was used as drug target.
Here the definition of the stoichiometry is different from
conventional definition of stoichiometry used to evaluate
drug efficiency. Conventional thinking in drug development
emphasizes stoichiometry which refers to the number of
drug binding per target molecule, which is also known as
Bmax· In this study the definition of stoichiometry refers to
the copy number of subunit within a biocomplex that serves
as drug target. We used phi29 viral components with a series
of variable but known stoichiometry as mock drug targets to
test the hypothesis. Both in vitro and in vivo virion assembly
assays were employed to compare the inhibition efficiency
targeting to components with different numbers of subunit
stoichiometry. Viral inhibition efficiency was analyzed with
Yang Hui's (Pascal's) Triangle (or knowns as binomial
distribution). It was found that inhibition efficiency on virus
replication correlates to the component stoichiometry of
nano-machine as drug target. It displayed power law inhibitory effect since when K=l, the percentage of uninhibited
biocomplexes in the population equal to q With the same
q and same K value, the inhibition efficiency is determined
by z, the number of subunits within the biocomplex or the
bio-machine as drug target. Here z serves as the power in the
equation, thus, the inhibitory effect is the power of the
stoichiometry. Empirical data demonstrated that the target
with thousand-subunits shows higher inhibition effect than
the targets with six subunits, and in turn higher than the
target with single subunit.
In evaluation of drug effect, two parameters were commonly used. One is the half maximal inhibitory concentra-
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tion (IC 50 ), which quantitatively indicates how much of a
particular drug is needed to inhibit a given biological
process by half. It is universally used as a measure of drug
potency in pharmacological research. Another important
parameter is the median lethal dose (LD 50 ), which is also
known as 50% of lethal concentration (LC 50 ). LD 50 is
frequently used to indicate a substance's acute toxicity.
Obviously, the usefulness of a drug will dependent on the
ratio of LD 50 to IC50 . The larger this ratio, the safer the drug.
By ways of increasing the inhibition efficiency through
targeting to the components with high stoichiometry, the
IC 50 of a drug will decrease. As a result, lower concentration
of drug will be required for reaching a desired effect,
resulting in a reduced toxicity of the drug.
Most of current anti-cancer, anti-virus or anti-bacteria
drugs target single enzymes or single proteins. Our data
showed that drugs selected to target components, biocomplexes, or nano-machines with high copy numbers could
lead to a much higher efficacy, and it could potentially solve
the problem of low drug effect and multi-drug resistance.
Conclusions
Targeting the functional biological units with higher stoichiometries will have a higher efficiency of inhibition. The
inhibition effect is power, other than proportional, and the
power, is the copy number of the drug-targeted element of
the machine. The new theory developed herein suggests that
potent drugs can be developed by targeting biocomplex with
high stoichiometry, and a complete inhibition of virus,
bacterium, or cancer is possible if a bio-machine with high
stoichiometry is identified. Since bio-motors share certain
common structure and operation mechanism in viruses,
bacteria, and cells, this approach should have general application in drug development.
Living systems contain many elegant arrays, motors and
nanomachines that are multi-subunit complex. As reported
here, these biocomplex with high copy number of components can serve as potent drug targets. For example, most
members of the AAA+ family are hexamer [19,87,88,106,
107,108]. However, these machines are common in living
systems therefore the specificity and toxicity is an issue. For
bacteria and virus, since our goal is to kill them nonexclusively, the specificity and toxicity is not an issue as long as
the target biocomplex is not identical to that in human body.
For cancers drugs, as long as a mutation is found in the
multiple-subunit biocomplex, it will be an ideal target for
potent drug.
Disclosed Method(s)
A method is disclosed herein for developing potent drugs.
Drug inhibition potency depends on the stoichiometry of the
targeted biocomplex.
Approach:
Phi29 viral components with variable stoichiometry were
used as model to prove the hypothesis. Virion assembly
efficiency was assayed and analyzed with Yang Hui's Triangle:

thousand-subunit showed higher inhibition effect than with
six subunits, and in turn higher than target with single
subunit. A complete inhibition of virus, bacterium, or cancer
was demonstrated when targets with high stoichiometry was
used as target.
Conclusions
Drug inhibition potency depends on the stoichiometry of
the targeted components of the biocomplex or nano-machine. The inhibition effect displayed a power function of
the stoichiometry of the target biocomplex. Since binmotors share certain common structure and operation
mechanism in viruses, bacteria, and cells, this approach
should have general application in drug development.
Section 2
Multidrug resistance and the appearance of incurable
diseases inspire the quest for potent therapeutics.
A new methodology in designing potent drugs is developed by targeting multi-subunit homomeric biological
motors, machines, or complexes with Z>l and K=l, where
Z is the stoichiometry of the target, and K is the number of
drugged subunits required to block the function of the
complex. The condition is similar to the series electrical
circuit of Christmas decorations; failure of one light bulb
results in power-off of the entire lighting system. In most
multisubunit homomeric biological systems, a sequential
coordination or cooperative action mechanism is utilized,
thus K equals 1. Drug inhibition depends on the ratio of
drugged to non-drugged complexes. When K=l, and Z>l,
the i_nhibition effect follows a power law with respect to z,
leadmg to enhanced drug potency. The hypothesis that the
potency of drug inhibition depends on the stoichiometry of
the targeted biological complexes was recently quantified by
Yang-Hui's Triangle (or binomial distribution), and proved
using a highly sensitive in vitro phi29 viral DNA packaging
system. Examples of targeting homomeric bio-complexes
with high stoichiometry for potent drug discovery are discussed.
Biomotors with multiple subunits are widespread in
viruses, bacteria, and cells, making this approach generally
applicable in the development of inhibition drugs with high
efficiency.
The continuous escalation of drug resistance has been
threatening human health and life, i.e., many microorganisms including bacteria, viruses, and even cancer cells are
developing resistance to current chemotherapies. Drug resistance in cancer has partially contributed to -600,000 deaths
in the USA in 2012[1]. To combat the on-rising drug
resistance, different approaches for developing new drugs
have been explored. One method is to develop drugs that
target new mechanisms. Components highly important for
cancer cell growth have been explored as drug targets for the
treatment of multi drug resistant cancer[2, 3]. The first 1-DAapproved drug to treat multidrug-resistant tuberculosis,
bedaquiline, follows a new mechanism of inhibiting the
bacterial ATP synthase of M. tuberculosis and other mycobacterial species[ 4]. Another approach is to use nano-drug
carriers to enhance the binding efficiency of drugs to cancer
cells[5-8]. A third approach is to develop new combinational
drugs acting on multiple targets to enhance its efficacy [9,
~OJ, incl~ding cocktail therapy[ll]. This involves identifymg multiple targets that when treated simultaneously lead to
a synergetic therapeutic effect and optimizing the design of
multi-target ligands[12]. Still, there is unmet need for treating multi-drug resistant disease. Thus, new approaches for
drug development are needed to combat drug resistance.
A new hypothesis that potent drugs can be developed by
targeting proteins or RNA complexes with high subunit
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stoichiometry was reported recently[13]. The major challenge for testing this hypothesis is to evaluate the significance of the target stoichiometry and the binding affinity of
the drug molecule with respect to its efficacy. In order to
quantitatively correlate the drug inhibitory efficacy to the
stoichiometry of the target biocomplexes, a well-studied
multicomponent system is required, which allows an empirical comparison of functional inhibition efficiency of individual components with different numbers of subunits.
The DNA packaging motor of bacteriophage phi29 was an
ideal model for testing this theory. The morphology and
stoichiometry of the individual components in the phi29
DNA packaging motor have been well studied. The Phi29
biomotor (FIG. lA) is composed of three essential, coaxially stacked rings[14-17]: a dodecameric connector ring
located at the vertex of the viral procapsid; a hexameric
packaging RNA (pRNA) ring bound to the N-terminus of the
connector[16, 18], and a hexameric ring of ATPase gp16
attached to the helical region ofpRNA[19-21]. The stoichiometry of pRNA was first determined using Yang Hui's
Triangle (or binomial distribution) in 1997[22], and similar
mathematical methods were applied to determine the stoichiometries of the protein subunits [14]. Furthermore,
dsDNA packaging utilizes a revolution mechanism without
rotation to translocate its genomic DNA powered through
the hydrolysis of ATP[20, 21, 23-28]. The copy number of
ATP molecules required to package one full Phi29 genomic
dsDNA has been predicted to be 10,000[20, 21, 23-27, 29].
Phi29 DNA packaging, thus, offers an ideal platform to test
the concept described above: the dependence of the inhibitory drug efficiency on the stoichiometry of its targeted
biocomplex.
Although the theory of targeting multisubunit complexes
for developing potent drugs was reported and validated
recently[13], real cases of targeting multisubunit complex
for new drug development have been practiced[30-32].
Since multicomponent biomotors are widely spread in
nature[26, 27, 33, 34], the approach of targeting multisubunit complexes for potent drug development discussed here
is generally applicable, especially in developing new generations of drugs for combating the rising acquired drug
resistance in viruses, bacteria, and cancers [35-37].
Rationale for Selection of Multi-Subunit Biocomplexes as
Efficient Drug Targets
Inhibitory drugs are typically designed to bind selectively
to a target site, thereby blocking the site from interaction
with other biomolecules leads to the loss of essential activity
of the biological target. This target can be a single element,
composed of only one subunit, or a complex consisted of
multiple subunits, such as the biomotors of the hexameric
ASCE (Additional Strand Catalytic E) superfamily[20, 38].
Conventional drugs are designed to inhibit pathogenesis
through targeting of a single subunit molecule, such as an
enzyme or a structural protein of a virus. As discussed
below, the key in designing potent drugs lies in targeting
multisubunit biological motors, machines, or complexes as
drug targets that follow a sequential coordination or cooperative mechanism. The stoichiometry of the complex, Z, is
larger than 1 and the number of drugged subunits that are
required to block the activity of the target complex, K,
equals 1 (Z> 1 and K = 1). Similar to in-series connected
decorative Christmas lights, where one broken light bulb
will tum off the entire chain, one drugged subunit will
inhibit the entire complex and therefore biological activity.
Sequential action or cooperativity in multisubunit complexes has been widely reported in biological systems[39-

43]; inhibiting any subunit leads to inhibition of the entire
complex, or in other words K equals 1.
For a conventional drug that inhibits its single subunit
target (Z=l) with efficiency p, the fraction of undrugged
target molecules q will be 1-p; and those undrugged target
molecules will remain active to maintain their biological
function. In this situation, the inhibition efficiency is proportional to the substrate targeting efficiency p[39-41].
When targeting a dimeric complex (Z=2), for example,
inactivating any subunit results in inhibition of the whole
complex. For a drug targeting a dimeric complex with
substrate targeting efficiency p=0.9 (90%), only 10% of the
first subunit and 10% of the second subunit remain active
after drug targeting. Thus, the fraction of undrugged complexes will be effectively reduced to 0.01, leaving 1% of
complexes active. Since drug inhibition depends on the ratio
of drugged to undrugged complexes, the efficiency of the
inhibition is proportional to the product of the inhibition of
the individual subunits, in other words, it follows a power
law with respect to Z.
Consequently, a complex composed of Z subunits with the
smallest number of blocked subunits (K) to inhibit activity
of the complex is 1, when p percent of subunits are interacting with the drugs, the fraction of uninhibited biocomplexes will be q and the proportion of inhibition equals
1-qz.
2.1 Drug Inhibition Efficiency Predicted by Binomial
Distribution Model
The scenario outlined above follows a binomial distribution which can hence be used to outline the relation between
drug inhibition efficiency and target stoichiometry in general. When the target element is a monomer, the inhibition
efficiency can be calculated using Equation 1, where p and
q are the fractions of drugged (substrate targeting efficiency)
and undrugged (normal active elements) subunits, respectively (p+q=l).
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Computational results based on the binomial equation are set
forth herein. The context of the results governs which form
of the equation is used.
The probability of drugged subunits (M) and undrugged
subunits (N; M+N=Z) in any given biocomplex can be
determined by the expansion of Equation 2. When Z=3, The
expanded form of Equation 2, (p+q)3=p 3 +3p 2 q+2pq2 +q3 =1,
displays the probabilities of all possible combinations of
drugged and undrugged subunits of a homotemary complex
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composed of three (p 3 ), two (p 2 q), one (pq2 ), or no (q3 )
drugged subunits; the sum equals 1. Assuming that 70%
(p=0.7) of subunits are inactivated by bound drugs leaving
30% (q=0.3) unaffected, then the percentage of complexes
possessing at least two copies of normal subunits would be
the sum of those possessing one copy of drugged and two
copies of undrugged wild-type subunits, 3pq2 , and those
possessing three copies of native subunits is q 3 , i.e., 3pq2+
q3=3(0.7)(0.3)2+(0.3)3=0.216. In another example, if a
complex contains 6 subunits, and biological activity requires
5 out of the 6 subunits to remain uninhibited, the fraction of
active complexes in the total population equals the sum of
probabilities of obtaining: 1) 5 and 2) 6 undrugged subunits.
Using the binomial distribution, the probabilities that a
population contains any combination of undrugged versus
drugged subunits can be predicted. The effect of the targeting efficiency p on the probability of obtaining a given
complex with M drugged and N undrugged subunits is
displayed in Table 1. The probabilities are calculated using
equation 2,

nature of biological reactions, we suggest that targeting of
multi-subunit biocomplexes can serve as a tool to develop
highly potent drugs. In a conventional six-component system, when one drug is designed to target only the component
#3 to stop the entire system, such a condition resembles the
model in equation 2 with Z= 1 and K = 1. Thus, the inhibition
efficiency is linear to the substrate targeting efficiency (p) of
the drug. However, in a homohexameric component system,
the entire complex is blocked when a drug targets any
subunit of the hexamer, which resembles Z=6 and K=l.
Thus, the probability of active target complexes equals q 6
(q=l-p). In other words, the drug inhibition efficiency is
equal to l-q 6, which scales with the 6th power of q compared
to linearly with q as for conventional mono-subunit
approaches (see Table 1).
Targeting a biological complex that exhibits a higher
stoichiometry substantially reduces the fraction of noninhibited complexes. K=l implies that drug binding to one
subunit inactivates the subunit, in which one drugged subunit is sufficient to inhibit the function of the entire complex.
As an example, a probability calculation for Z=6 and K=l is
given below. As all 6 (Z=6) copies of the subunits are
required for function, while one drugged subunit (K=l) is
sufficient to block the activity, all elements possessing 1
through 5 copies of drugged subunits are non-functional
(FIG. lC). Only those complexes possessing 6 copies of
undrugged subunits are functional. The probability that a
complex contains 6 copies of unaffected subunits is q 6 and
therefore the inhibition efficiency is l-q 6 [12, 23, 39, 46, 51,
52].
Consequently, for a drug with binding efficiency p, a
larger stoichiometry of the target complex substantially
increases the inhibition efficiency. To illustrate, we compare
the fraction of non-inhibited complexes for Z=6 and Z=l,
while keeping q=0.4 and K=l fixed for both target systems.
The fraction of non-inhibited complexes for Z=l amounts to
q2 =0.4 1 =0.4, resulting in 1-0.4=60% of inhibited complexes. In contrast, for Z=6, the fraction of non-inhibited
complexes
is
q2 =0.4 6=0.0041
and
therefore
1-0.0041=99.59% of complexes are inhibited. The ratio of
the remaining non-inhibited complexes (0.4/0.0041 =98)
shows a 98-fold decrease in non-inhibited complexes for
Z=6 compared to Z=l. At a targeting efficiency ofp=0.9, the
inhibition efficiency for Z=6 is l-q2 =1-0.l 6=0.999999
resulting in a 10,000-fold increased inhibition efficiency
compared to Z=l (0.1/0.1 6=105 , see Table 1). The binomial
distribution indicates that the inhibitory effect follows a
power law with respect to the stoichiometry of the target.
Thus, for K=l, the fraction of uninhibited biocomplexes
equals q2 ; the larger Z, the smaller q2 , (as 0<q<l). That is to
say when developing drugs with the same binding affinity to
their targets, the higher the stoichiometry of its multimeric
target, the fewer uninhibited targets will remain and the
more efficient the drug will be.
2.3 IC 50 Decreases as the Stoichiometry of Target Complexes Increases
The half maximal inhibitory concentration (IC 50 ) is one
parameter used to evaluate drug efficacy. It quantitatively
indicates how much of a particular drug is required to reduce
the activity of a given biological process by half. It is
universally used as a measurement of drug potency in
pharmacological research. The median lethal dose LD 50 ,
also known as 50% of lethal concentration, is an important
parameter to evaluate the safety profile, i.e., acute toxicity of
a drug. Most importantly, a larger ratio of LD 50 to IC 50 ,
results in a safer drug. By increasing the inhibition efficiency
through targeting components with high stoichiometry, the
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obtained from Yang Hui's Triangle, which is also called
Pascal's Triangle, or binomial distribution (FIG. 18)[44].
The use of Yang Hui's Triangle and binomial distribution to
determine the stoichiometry of biological motor was published in Guo Lab in 1997[22, 45] for RNA component and
restated in 2014 for protein component[14] in phi29 DNA
packaging motor.
2.2 Cooperativity in Multisubunit Biocomplexes Leads to
High Inhibition Efficiency
The cooperativity of multisubunit biocomplexes is the
key to high drug inhibition efficiency. Cooperativity means
that multiple subunits work sequentially or processively to
accomplish one essential biological reaction [23, 40-42,
46-50]. Blocking any subunit of the complex inhibits the
activity of the whole complex. Many reactions involving
multiple subunits work cooperatively, e.g. assembly pathways in viral assembly systems [39, 51]. An analogy to such
a biological reaction mechanism is given by the difference
between parallel and series circuits. When a chain of light
bulbs is arranged in a parallel circuit, burning out one light
bulb will not affect others, while in a series circuit, breaking
any one light bulb turns off the entire lighting system. The
K value, the smallest number of subunits that needs to be
inhibited in order to inhibit function of the light chain is
therefore, K=l. Thus, the K value is a key factor in estimating the probability of obtaining inactive nanomachines
or biocomplexes by combination and permutation of all
subunits.
K=l is critical for obtaining ultrahigh inhibition. The
foundation of the approach in this report is the difference in
inhibition probability for biocomplexes with the same ratio
of drugged target subunits but different K values. Biological
systems display complicated reactions that involve several
steps and multiple components interacting in series or parallel Based on the binomial math model and cooperative
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effective drug dosage is greatly decreased, thus decreasing
the IC 50 . As a result, the ratio of LD 50 to IC 50 increases,
resulting in an enlarged therapeutic window of the drug.
Ifwe denote Picso as the percentage of drugged subunits
needed to reach 50% inhibition, then l-(1-Picso)2=50%
Solving this equation Picso=l-0.5 112. FIG. 8, shows the
relationship between stoichiometry (Z) and drug targeting
level p to reach the inhibition effect (IC), where p is a
combined result of drug binding efficacy and drug concentration (dosage). When the stoichiometry Z of the multimeric drug target increases, the dosage of drug to reach IC 50 ,
IC 20 , or IC 80 decreases, presented by the percentage of
drugged subunits. This clearly shows that as Z increases,
Picso decreases, and hence the drug is more potent.
Focusing on the stoichiometry of the target complex for
drug development differs from conventional approaches.
Conventional drug molecules are sought to have a high
binding affinity to the target, which means we expect more
drug molecules to bind to one target molecule. Here stoichiometry refers to the copy number of subunits within a
biocomplex or nanomachine that serves as the drug target.
This idea agrees with a newer model for predicting clinical
drug efficacy, the receptor occupancy. Receptor occupancy
acts as a predictor for human pharmacodynamics and antihistamine potency and takes into account both the affinity of
the drug for its receptor and its free plasma concentration
[53].
Inhibition Efficiency as a Power Function of Target Stoichiometry Proved by Phi29 Viral Assembly System
The hypothesis that drug inhibition efficiency follows a
power function with respect to the target stoichiometry has
been proved using the Phi29 viral assembly system [54].
This well-defined in vitro assembly system is composed of
four components, each of which is comprised of different
subunits that can act as the nano-machine target. Inhibition
of viral assembly is achieved using mutant components that
represent drugged target components. The inhibition efficiencies were analyzed with Yang Hui's triangle for targeting each of the Phi29 DNA packaging motor components.
Binomial distribution analysis of these viral assembly competition assays confirmed the concept that drug targeting
biological complexes with higher stoichiometry results in a
higher efficiency than drugs acting on a single subunit target.
The highly sensitive in vitro Phi29 assembly system was
used to determine the inhibition efficiency of drugs targeting
multi-subunit complexes [22, 39, 45, 55], thus validating a
new method for developing potent drugs. The bacteriophage
Phi29 DNA packaging motor contains one copy of genomic
dsDNA, 6 copies of packaging RNA, 6 copies of ATPase
protein gpl 6, and consumes more than 10,000 copies of ATP
during genome packaging. The hexameric stoichiometry of
Phi29 pRNA has been extensively shown using singlemolecule techniques[54], AFM imaging[56, 57], pRNA
crystal structure determination[58], and statistical evaluations[22]. The hexameric stoichiometry of Phi29 gp16 has
been proved by native gel binding, capillary electrophoresis
assays, Hill constant determination, and by titration of
mutant subunits using binomial distribution[20, 23]. The
copy number of ATP molecules was calculated based on the
fact that 6 ATP molecules are required to package one pitch
of dsDNA containing 10.5 base pairs [59], thus one ATP is
used to package 1. 7 base pairs of dsDNA. The entire Phi29
genome is composed of 19,400 base pairs, thus, it is
expected that more than 10,000 ATP molecules are required
to package an entire Phi29 genome. The availability of a
motor system with multiple well-defined and characterized
components makes an ideal disease model for the analysis of

drug inhibition efficiency versus the subunit stoichiometry
of individual subcomponents within the same assay.
Inhibition efficiencies were determined for ATP, pRNA,
ATPase gp 16, and DNA as drug targets with stoichiometries
of 10,000, 6, 6, and 1, respectively. Among these components, targeting of ATP showed the strongest inhibition,
while drugged mutant pRNA and mutant gp16 still showed
stronger inhibitory effects than mutant DNA (FIG. 3). For
example, adding 20% mutant DNA caused 20% inhibition of
viral assembly, while 20% of drugged mutant pRNA exerted
74% of inhibition on viral assembly and 20% of y-S-ATP
almost completely inhibited the viral assembly, indicating
that higher stoichiometry results in stronger inhibition efficacy.
The target with ten-thousand-subunits showed higher
inhibition than those with six subunits, which in tum showed
higher inhibition than the single subunit target. In conclusion, these results show that inhibition efficiency displays a
power function with respect to the stoichiometry of the
target biocomplexes. Drug inhibition potency depends on
the stoichiometry of the targeted components of the biocomplex or nano-machine. Since bio-motors share certain
common structural and operational mechanisms across
viruses, bacteria, and other cells, this approach has general
application in drug development.
Wide-Spread Distribution of Biomotors with Multiple
Subunits or High Order Stoichiometry
Biological systems contain a wide variety of nanomachines with highly ordered stoichiometry that are essential
for DNA replication, DNA repair[60], homologous recombination, cell mitosis, bacterial binary fission, Holliday
junction resolution[61], viral genome packaging[62], RNA
transcription, nuclear pore transport, as well as motion,
trafficking, and exportation of cellular components. Here we
use biological motors as an example to elucidate the rationale of Z> 1 and K = 1. These biological motors can generally
be classified into three categories according to their DNA
transportation mechanism: linear motors, rotation motors
and the newly discovered revolution motors[23, 27, 34].
High order stoichiometries are wildly observed among biomotors, especially in rotation and revolution motors. Thus,
biomotors are feasible targets for the development of potent
inhibitory drugs that exploit the power law behavior of the
subunit stoichiometry.
4.1 Rotation Nanomachines
FoFl ATP synthase and helicases are representatives of
rotary motors [63, 64]. FoFl ATP synthase is a ubiquitous
membrane enzyme that plays a key role in biological energy
metabolism [65, 66]. It consists of two linked rotary motors,
Fl and Fe, which are distinct in structure and function. Fl
ATPase, forming the catalytic core, shows strong ATP
hydrolysis activity. It is composed of 5 subunits
(a 3 ~ 3 y1 01 E 1 ), with three a and three~ subunits forming a
hexameric ring with part of a long coiled coil y subunit. Fo
is the proton pore that is embedded in the membrane, it
consists of at least 3 subunits (a 1 b 1 c 8 _15 ) whereby subunit c
differs among species.
Helicase DnaB is a hexameric nanomachine (FIG. 4A)
that unwinds dsDNA in front of the replication fork during
DNAreplication[67, 68]. Recently, a hand-over-hand translocation mechanism was proposed for DnaB based on the
crystal structure of the DnaB hexamer complexed with
ssDNA and GDP-AIF4 [69]. In this mechanism, the 5'-3'
translocation of the subunits at a stepsize of two nucleotides
is coupled with the sequential hydrolysis of NTP [70]. The
sequential hand-by-hand migration of the individual subunits results in DNA translocation.
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RecA, a family of ATP-dependent recombinases, plays an
important role in dsDNA repair and genetic recombination
in Archaea, Bacteria, and Eukaryota. It can interact with
ssDNA forming right-handed helical filaments as a complex
with approximately six monomers of RecA per turn (FIG.
48)[71, 72]. Electron microscopy studies have demonstrated
that ATP binding induces a re-orientation between the RecA
ATPase domains, resulting in the relative rotation of the
protein on DNA substrate during DNA translocation powered by ATP hydrolysis.
4.2 Revolution Nanomachines
All the dsDNA viruses known to date utilize similar
mechanisms to transport their genome into preformed protein shells during replication. For example, Bacteriophage
phi29, HK97, SPPl, P22, and T7 all share a common
revolution mechanism for dsDNA packaging that employ a
hexameric ATPase and predominantly dodecameric connector channels for packaging dsDNA. The phi29 DNA packaging motor is composed of three coaxial rings: a dodecameric channel ring and an ASCE hexameric ATPase linked
by a hexameric ring of pRNA (FIG. 4C)[20, 54, 58]. During
genome packaging, more than 10,000 ATP molecules are
consumed by the hexameric ATPase as energy source to
drive the translocation of one copy of the dsDNA genome
[59].
The ASCE superfamily, including FtsK-HerA superfamilies and the AAA+ (ATPases associated with diverse cellular
Activities), is a clade of nanomachines that display a hexameric arrangement[73-76] of subunits. Their biological
function is to convert chemical energy from ATP into
mechanical motion[20, 29, 77, 78], typically associated with
conformational changes oftheATPase enzyme [20, 79, 80].
FtsK belongs to the ASCE superfamily. It is a multidomain protein composed of a C-terminal ATPase domain
FtsK(C) containing a, ~ and y sub-domains, an N-terminal
membrane-spanning domain FtsK(N) and a 600-amino acid
linker[81-83]. It is responsible for conjugation between
bacterial cells and dsDNA bidirectional translocation[84,
85]. It has been proposed that FtsK subunits acts in a
sequential manner employing a revolution mechanism to
translocate dsDNA[86, 87]. The crystal structure and electron microscopy of FtsK(C) demonstrates formation of a
ring-like hexamer with DNA passing through the hexameric
ring (FIG. 4D)[87, 88].
Targeting Biocomplexes for Developing Potent Drugs
As illustrated above, drug efficiency follows a power
function of the stoichiometry of the subunits of the multimeric target biocomplex. Targeting biocomplexes with
higher stoichiometry therefore can lead to the development
of more potent drugs. Experimentally, approaches targeting
receptor dimers, hetero- and homo-oligomers for drug
screening open exciting possibilities for drug discovery and
development[89].
Targeting Homomeric Channel Proteins for Drug Development
In the history of drug development, one important property of most channel protein receptors has been overlooked,
their stoichiometry. As a matter of fact, many channel
proteins are expressed as dimers or oligomers on cell
membrane, including most G-Protein-Coupled Receptors
(GPCR) proteins [89]. Targeting of GPCR hetero- and
homo-oligomers is generally starting to be considered for
drug development. Therefore, new models for multisubunit
protein binding are being developed[89]. Cooperative binding affinity between ligand and multi subunit targets has been
reported and cooperativity factors were calculated by fitting
to the Hill equation[23, 89].

The ATP-sensitive homotrimeric P2X7 receptor (P2X7R)
acts as a ligand-gated ion channel. It forms a chalice-like
channel with three ATP binding sites localized at the interface of the three subunits. Occupancy of at least two of the
three sites is necessary for activation of the receptors which
results in opening of the channel pore allowing passage of
small cations (Na+, Ca2 +, and K+). P2X7R has received
particular attention as a potential drug target for its widespread involvement in inflammatory diseases and pivotal
roles in central nervous system (CNS) pathology [30]. These
concepts will broaden the therapeutic potential of drugs that
target multi-subunit channel proteins, including receptor
heteromer-selective drugs with a lower incidence of side
effects. They will also help to identify new pharmacological
profiles using cell models that express heteromeric receptors.
Targeting Homomeric Enzyme for Antibiotics Development
Targeting of key enzymes in essential biosynthesis pathways is an important approach for antibiotics development.
Many key proteins in the fatty acid synthesis pathway and
nucleotide synthesis pathway are found to be multivalent.
The highly ordered oligomeric enzymes in biosynthesis
pathways could be promising targets for developing more
potent antibacterial drugs. Some examples of developing
potent drags by targeting multisubunit biocomplexes are
discussed below.
Fatty acid synthesis is an essential lipogenesis process in
both Gram-positive and Gram-negative bacteria. A key
enzyme in the fatty acid biosynthesis pathway is fatty acid
biosynthesis 1 (FabI), which is a homotetramer complex
acting as the major enoyl-ACP reductase present in Burkholderia pseudomallei (8pm). A recent X-ray structure
study revealed the binding mode of the inhibitor PT155 with
the homo-tetrameric BpmFabI [31] (FIG. SA). The substrate
BpmFabI is a homo-tetramer, one PT155 molecule bound to
each monomeric subunit has shown significant promise for
antibacterial drug development[31]. Another example of
targeting multisubunit biocomplex as drug target is found in
the guanine nucleotide biosynthesis pathway to control
parasitic infection. Inosine 5'-monophosphate dehydrogenase (IMPDH) is a homo-tetramer enzyme[32](FIG. 5B),
which plays an important role by catalyzing the oxidation of
IMP to XMP in guanosine monophosphate (GMP) biosynthesis[32]. Structural characterization of IMPDH with
chemical inhibitor drugs indicates that binding to the repeating units shows a more potent inhibition effect[90].
These examples of successfully targeted homotetramer
enzymes for potent drug development further proved the
importance of the stoichiometry of target homo-meric complexes. When applying this method to search enzymes as
drug targets, it is critical to test whether the stoichiometry of
the complexes (Z) is > 1, and the number of subunits needed
to inhibit to block biological function (K) equals 1.
Targeting Homomeric Drug Transporters for Drug Development
The mechanism of drug transporter, very similar to that of
the revolution motor, involves entropy induced transitions
by ATP. High stoichiometry of the target complex is a key
consideration in drug efficiency. Targeting multidrug efflux
transporters with high stoichiometry has a better chance to
develop drugs for treating multi-drug resistant disease. The
structure of bacterial multidrug efflux transporter AcrB is
composed of three alpha-helix subunits, that connect to form
a funnel around a central cavity (FIG. 5C)[91]. The multidrug exporter MexB from Pseudomonas aeruginosa also
forms a homotrimer (FIG. 5D)[92]. Pyridopyrimidine
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derivatives have been reported to be promising drugs to treat
multidrug resistant pathogens by specific inhibition of the
homotrimeric AcrB and MexB transporters[ll 7]. The structural architecture of ABC transporters consists minimally of
two TMDs and two NBDs. These four individual polypeptide chains combine to form a full transporter such as in the
E. coli BtuCD[93]. Although the stoichiometry of the heterodimer is not very high, the stoichiometry of ATP per
transporter is high. It is involved in the uptake of vitamin
B12. The TMDs of ModBC-A and MalFGK2-E have six
helices per subunit. These unique structural features can be
used in target considerations.
Conclusion and Future Perspective
Targeting functional biological units with higher stoichiometries allows for higher inhibition efficiencies. The
inhibition efficacy follows a power law with respect to the
subunit copy number when targeting multimeric biocomplex, compared to a linear effect of the drug-target binding
affinity when targeting a single-subunit substrate. This new
concept outlined herein suggests that potent drugs can be
developed by targeting biocomplexes with high stoichiometries with the potential of complete inhibition of the targets
activity. Possibly, this method can further be applied to guide
development of dominant negative proteins for potent gene
therapy, which can be incorporated into a multimeric protein
nanomachine and results in a change of its activity [94].
Since bio-motors share certain common structural and
operational mechanisms across viruses, bacteria, and cells,
this approach has general applicability in drug development.
Living systems contain many elegant arrays, motors and
nanomachines that are composed of multiple identical subunits. As reported here, these homomeric biocomplexes can
serve as potent drug targets. For example, most members of
the ASCE family are hexamers[20, 95-99]. As these
machines are common among living systems, specificity and
toxicity need to be considered. In the development of
anti-bacterial and anti-viral drugs, specificity and toxicity is
not problematic since the target biocomplexes differ from
those found in human cells and thus all targets are intended
to be killed nonexclusively. In the development of anticancer drugs, mutations in multiple-subunit biocomplexes of
cancer cell will present ideal targets for potent drug development.
Expert Opinion
Drug discovery is a multidisciplinary science including
the fields of medicine, biotechnology and pharmacology.
Aiming to find a method for developing drugs with ultrahigh potency, much effort has been placed in the screening
of new drug compounds, uncovering of new drug targets,
and illumination of functional pathways, but little attention
has been paid to the exploration of new methods for the
design and development of more efficient drugs. Here we
propose that the inhibition efficiency of a given drug
depends on the stoichiometry of the biocomplex or biomachine that serves as drug target. Here the notion of
"stoichiometry" differs from the conventional concept in
drug development. Conventionally, stoichiometry refers to
the number of drug molecules bound to each substrate or cell
membrane. In the current study stoichiometry refers to the
number of identical subunits that the target biocomplex is
composed of. Phi29 viral components with a series of
variable but known stoichiometries were evaluated as mock
drug targets to test the hypothesis. Both in vitro and in vivo
virion assembly assays were employed to compare inhibition efficiencies for targets with differing subunit stoichiometries. Viral inhibition efficiency was analyzed with Yang

Hui's (Pascal's) Triangle (also known as binomial distribution) (FIG. 1), as shown in equation 2.
It was observed that inhibition efficiency of virus replication correlates with the stoichiometry of the drug target.
The inhibition efficacy follows a power law behavior where
the percentage of uninhibited biocomplexes equals q2 (see
equation 2). For a system with fixed q and K values, the
inhibition efficiency thus depends on Z, the number of
subunits within the target biocomplex or bio-machine. This
hypothesis is supported by empirical data that a target with
ten-thousand-subunits shows higher inhibition effect than a
target with six subunits, which in tum shows higher inhibition than a single-subunit target (FIG. 3). The unconventional hypothesis described in this article for the development of potent drugs with power function behavior with
respect to the target stoichiometry can be foreign or even
outlandish to the main force of the pharmaceutical field. The
approach of developing highly potent drugs through targeting of protein, RNA or other macromolecule complexes with
high stoichiometry has never been reported due to challenges to prove the concept.
Traditionally, it is almost impossible to prove this concept
by comparing efficacies of two drugs where one of them
targets a biocomplex with multiple subunits. When reporting
the efficiency of this new approach, it is very difficult to
distinguish essentiality of the two targets in biological
function, it is also very challenging to compare the binding
affinity of two different drugs to two different targets. For
instance, if two drugs target two stoichiometrically different
complexes, it becomes extremely difficult to prove whether
the difference in drug efficiency is due to differences in their
target binding affinity or essential level of the target in the
biological organism.
The mechanism of drug inhibition mainly relies on blocking an essential biological target element from functioning.
The target elements can be monomers or a complex of
multiple homosubunits; such as the biomotors of the hexameric ASCE superfamily[20, 38]. Conventional drugs are
designed to target a single subunit molecule to inhibit
pathogenesis, such as an enzyme or a structural protein of a
virus. The key in designing potent drugs is to target multisubunit biological motors, machines, or complexes with Z> 1
and K=l, where Z is the stoichiometry of the complex and
K is the number of drugged subunit that are required in order
to block the function of the entire complex. Similarly, in a
series circuit Christmas decorative light chain, one broken
light bulb will tum off the entire lighting system.
In most, if not all, multi-subunit biological systems,
sequential coordination or cooperative action mechanisms
are utilized, thus, K equals 1. Drug inhibition depends on the
ratio of drugged to the non-drugged complex. For K=l, and
Z> 1, inhibition efficacy follows a power function with
respect to Z, leading to an increased potency of the drug
since inhibition of any subunit results in complete inhibition
of activity. For a drug designed to target a single-subunit
molecule at targeting efficiency p, the fraction ofundrugged
target molecules q that will remain active is 1-p. In this
situation, the inhibition efficiency is proportional to the
substrate targeting efficiency p and the inhibition efficacy is
of the first order of p. Sequential action or cooperativity in
multi-subunit complexes has widely been reported in biological systems[39-41]. Drugs targeting a complex with
multiple subunits can inhibit the complex activity if any
homosubunit of the target is inactivated. Thus, if the copy
number of this cooperative complex is Z> 1, and the least
number of blocked subunit to inhibit complex activity (K) is
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1, the fraction of uninhibited biocomplexes is q2 , and the
inhibition efficiency is l-q2 , where 1-q is the portion of
drugged subunits.
The binomial distribution analysis allows prediction of
the inhibition efficiencies. For example, in targeting a sixsubunit biocomplex with K=l, the inhibition efficiency is
determined by drug binding to any one of the six homo subunits. Therefore, the probability of inhibiting any subunit at
random position is

expressed or directly introduced, into a highly multimeric
complex that is identified as the target unit. For purposes of
serving as a small molecule drug target, a multimeric
complex might be identified, such that binding of one drug
molecule to any one binding site on the complex will
inactivate the whole complex. The fact that the complex
composed of Z subunits holding one drugged subunit will
only come into play as the drug concentration is at the high
end. However, if the strategy was to express a dominant
negative protein, as has been done in recent cardiac gene
therapy with dominant negative phospholamban[94], a high
inhibition efficacy will achieve. The greater the value of Z
the more the effect of the dominant negative protein subunit
or mutant subunit will be achieved.
Another possibility is the use of homomeric drug transporters [113, 114] as drug targets (see section 5.3). The
mechanism of drug transporters is very similar to that of the
revolution motor featuring an entropy transition induced by
ATP. High stoichiometry of target complex is a key consideration for achieving high drug efficiency. Targeting multidrug efflux transporters with high stoichiometry has a better
chance to develop drugs for treating multi-drug resistant
disease.
While the hypothesis behind this method might theoretically seem challenging, elucidation of the mechanism
should greatly facilitate application of this approach. Two
factors are essential for drugs development: efficiency and
specificity. The strategy described herein focuses on drug
efficiency, while specificity is similar to the general consideration in the development of chemicals and drugs. Nevertheless, design of potent drugs to common machines or
general targets is still possible. For example, if an oncogenic
mutant hexameric ATPase is found in one specific type of
cancer cells, drugs targeting to this mutation of the altered
ATPase will not only be highly efficient but also specific.
Using multisubunit homomeric complexes such as AAA+
family ATPase, biomotors or drug transporters with high
stoichiometry could lead to development of highly potent
drugs.
Most multisubunit complexes work in a sequential and
cooperative manner, that is K=l, which is the key for these
complexes to be used as target for potent drug development.
Bacterial virus Phi29 DNA packing motor contains many
multisubunit components with different stoichiometries; it is
a good model to elucidate the concept of stoichiometry in
drug development.
Multisubunit nanocomplexes such as biomotors or
ATPase are widely spread in nature. Thus, the method
should have broad application in the development of new
drugs. For example, the use of ATP synthase as drug target
has led to the development of a new drug for treating
multidrug resistant tuberculosis.
Section 3
Abstract
Aims:
To find a method for developing potent drugs and to prove
a hypothesis that drug inhibition potency depends on the
stoichiometry of the targeted biocomplex.
Methods:
Phi29 DNA-packaging motor components were used to
test this model for different stoichiometries. Viron assembly
efficiency was assayed with Yang Hui's Triangle:
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times higher than inhibiting a monomer substrate. With this
new elucidation and understanding of the concepts behind
targeting of cooperative multi-homosubunit complexes, a
new generation of potent drugs may emerge in the near
future.
Our discovery is an approach, not a drug. This approach
will have general impact in the development of drugs for
many diseases such as cancer, viral or bacterial infections. In
living systems, biological machines or complexes with high
stoichiometry and operated by sequential cooperative action
or coordination with Z> 1 and K = 1 are ubiquitous. This class
of biological machines is involved in many aspects of
crucial cellular processes to the survival of viruses, bacteria,
and eukaryotic cells. For example, multi-subunit biomotors
are involved in chaperon, ATPase, ATP synthase, cell mitosis, bacterial binary fission, DNA replication, DNA repair,
homologous recombination, Holliday junction resolution,
nuclear pore transportation, RNA transcription, drug transporters, muscle contraction, viral genome packaging, as well
as motion, trafficking, and exportation of cellular components. These systems use a sequential mechanism similar to
the serial circuit of the Christmas decoration lighting chain.
Thus, our approach will have broad application in drug
development in many biological systems. Drugs targeting to
these motors will be highly efficient.
Biomotors belonging to the multi-subunit ATPase are
widely spread in organisms, including bacteria, viruses and
cancer cells. Successful implementation of this new methodology will lead to the development of the next generation
of potent drugs. In fact the first drug approved to treat
multidrug-resistant tuberculosis, bedaquiline [4], is acting
on the ATP synthase which is a multisubunit biomotor
[100-111]. Treating multidrug-resistant tuberculosis had
been very challenging previously. Although this drug's
inventors were not aware of the concept of targeting multisubunit complexes for potent drug development, the success in this drug conquering the tough Mycobacterium
tuberculosis organism supports the concept of using the
multisubunit complex as a potent drug target. Cancer or
bacterial mutant multi-subunit ATPase can be used as target.
The drug developers can simply check the published literature and identify a multi-subunit machine as the drug target.
For cancer treatment, it is to find a multi-subunit machine
with mutation.
The concept of K = 1 for high efficiency inhibition may be
impactful in gene or protein therapy. By introducing the
dominant negative protein[94] or inactive mutant protein
into the cell, either by intracellular expression or direct
introduction of proteins, which resembles the above illustrated approach and mechanism used for phi29 DNA packaging motor systems [13, 14, 45, 112](FIG. 9). This involves
the incorporation of mutant proteins, either intracellularly
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where Z=stoichiometry, M=drugged subunits in each biocomplex, p and q represent the fraction of drugged and
non-drugged subunits in the population.
Results:
Inhibition efficiency follows a power function. When
number of drugged subunits to block the function of the
biocomplex K=l, the fraction of uninhibited biocomplex
equals q Thus, stoichiometry has a multiplicative effect on
inhibition. Targets with a thousand subunits showed the
highest inhibition effect, followed by those with six and a
single subunit. Complete inhibition of virus replication was
found when Z=6.
Conclusion:
Drug inhibition potency depends on the stoichiometry of
the targeted components of the biocomplex or nano-machine. The inhibition effect follows a power function of the
stoichiometry of the target biocomplex.
Introduction
Bacteria, viruses and cells contain biocomplexes and
nanomachines composed of multiple subunits, such as biomotors, pumps, exosomes, valves, membrane pores, chaperonins, PCNA, ATPase, and tubes. From a nanobiotechnological standpoint, these nanomachines can be used and
converted to build sophisticated nano-devices including
molecular sensors, patterned arrays, actuators, chips, microelectromechanical systems (MEMS), molecular sorters,
single pore DNA sequencing apparatus or other revolutionary electronic and optical devices. From a pharmaceutical
standpoint, these multi-subunit biocomplexes or nanomachines have a potential for use as drug targets for therapeutics, as well as diagnostic applications such as pathogen
detection, disease diagnosis, drug delivery, and treatment of
diseases. In the ASCE (Additional Strand Catalytic E)
family including the AAA+(ATPases Associated with
diverse cellular Activities) and the FtsK-HerA superfamily
in bacteria, viruses and cells, there are nanomotors that
perform a wide range of functions critical to chromosome
segregation, bacterial binary fission, DNA/RNA and cell
component transportation, membrane sorting, cellular reorganization, cell division, RNA transcription, as well as DNA
replication, riding, repair, and recombination. One of the
directions of NIH Roadmap is to utilize these cellular
nanomachines and biocomplexes for biomedical applications.
Acquired drug resistance has become a major reason for
failure treatment of a range of diseases, i.e., the chemotherapy for cancer, bacterial or viral infections. Drug resistance of cancer has escalated and has partially contributed to
the -600,000 deaths in the USA in 2012. HIV drug resistance has also become a major issue. Many common pathogens have become resistant to current drug treatments, with
new infectious diseases on the rise. The use of multidrugresistant agents in biological weapons has created a previously unrealized challenge. Thus, there is a need to develop
new treatment strategies to combat drug resistance with new
drug development methods.
The first FDA-approved drug to treat multidrug-resistant
tuberculosis, bedaquiline, follows a new mechanism of
inhibiting the bacterial ATP synthase of M. tuberculosis and
other mycobacterial species, but had little activity against
other bacteria. To combat multidrug resistance in cancer,
several approaches have been explored. One method is to
target components that are highly important for the growth
of the biological entity. Another approach uses nano-drug
delivery carriers that are expected to enhance the binding
efficiency of drugs to cancer cells, or cocktail therapy. A
third approach is to develop new combinational drugs with

higher potency by acting on multiple targets. This involves
identifying multiple targets that when treated leads to a
synergetic effect and optimizing the design of multi-target
ligands.
The approach of developing highly potent drugs through
targeting of protein or RNA complexes with high stoichiometry has never been reported due to challenges in comparing efficacies of two drugs that can be confused by target
essentiality with binding affinity. For instance, if two drugs
target two stoichiometrically different targets, it becomes
extremely difficult to prove whether the difference in drug
efficiency is due to differences in their target binding affinity
or essential level in the growth of the biological organism.
In order to quantify effects from targeting biocomplexes of
different stoichiometry, a well-studied multicomponent system is required that allows empirical comparison of functional inhibition of individual components that are composed of different number of subunits.
An example of one nanobiomachine is the dsDNA translocation motor, for which the ATPase protein is a pivotal
component that assembles into a hexameric ring structure
and translates the action of ATP binding and hydrolysis into
mechanical motion to translocate DNA physically. The DNA
packaging motor of bacteriophage phi29 (FIG. 12A) is
composed of three essential co-axial rings: 1) a dodecameric
connector ring located at the vertex of the viral procapsid; 2)
a hexameric packaging RNA (pRNA) ring (FIG. 12A, B)
bound to the N-terminus of the connector, and 3) a hexameric ring of ATPase gp16 attached to the helical region of
pRNA, powered through the hydrolysis of ATP resulting in
DNA packaging. The use ofYang Hui's Triangle or binomial
distribution to determine the stoichiometry of the pRNA was
first reported in 1997. The use of similar mathematical
methods to determine the stoichiometry of the protein subunits has also been reported more recently. The copy number
of ATP molecules required to package one full phi29
genomic dsDNA was predicted to be 10000. It has recently
been shown that this hexameric motor uses a revolution
mechanism without rotation to translocate its genomic
DNA.
In this report, we hypothesize that the inhibitory efficiency
of a drug is related to the stoichiometry of its targeted
biocomplex; the higher the stoichiometry of the target complex, the more efficient the drug. This can lead to the
development of potent therapeutics against high-stoichiometric biomachines or biocomplexes as drug targets. We
proved this hypothesis by using a mutant subunit as the
drugged inactive target to calculate the theoretical inhibition
efficiency via binomial distribution, and compared with
experimental data from a defined in vitro viral assembly
system. Since biomotors share certain common structures
and operation mechanisms, the approach in drug development reported here should have general applications especially in developing new generations of drugs for combating
the rising acquired drug resistance in viruses, bacteria, and
cancers.
Materials and Methods
Preparation of Mutant Genomic dsDNA
Phi29 genomic DNA-gp3 was purified from B. subtilis
SpoA12 cells by CsCl gradient ultracentrifugation as
described previously. Mutant dsDNA was prepared by
digesting the phi29 genomic dsDNA with EcoRl restriction
enzyme in fast digest buffer (Fermentas) at 37° C. for 1 hour
followed by ethanol precipitation. The mutant DNA was
tested by 1% agarose gel electrophoresis, stained by
ethidium bromide (Sigma) and imaged by Typhoon (GE).
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Preparation of Mutant pRNA
Wild-type phi29 pRNA and inactive mutant as drugged
pRNA were prepared by in vitro transcription. In the inactive
mutant pRNA, the first four bases "UUCA" (SEQ ID NO:
11) located at the 5' end were mutated to "GGGG" (SEQ ID
NO: 11). Bg!II digested plasmid pRT71 was used as DNA
template in the PCR reaction for both RNAs. Oligonucleotide 5'-TAA TAC GAC TCA CTA TAG GGG TGG TAC-3'
(SEQ ID NO: 12) and 5'-TTA TCAAAG TAG CGT GCA
C-3' (SEQ ID NO: 13) were used as primers for mutant
pRNA. RNAs were then transcribed by T7 RNA polymerase
using double-stranded DNA generated from PCR, as
described before. The RNA from in vitro transcription was
further purified by 8 M urea 8% polyacrylamide gel electrophoresis as described previously.
Preparation of Mutant ATPase Gp16
The purification of wild-type gp16 has been described
previously. The walker B mutant gp16 was constructed by
introducing mutations in the gp16 gene. The amino acid
residues D255 and E256 in walker B motif of gp16 were
mutated to E255 and D256, respectively. The mutation was
introduced with the Stratagene Quick Change site-directed
mutagenesis kit using appropriate primers. The expression
and purification of protein were carried out followed a
published procedure.
Antisense Oligonucleotides
Antisense oligonucleotides P3 and P15 were designed to
be reversely complementary to different regions on the
pRNA molecule and chemically synthesized by IDT. P3
oligo (5'-TTGCCATGATTGACAAC-3' (SEQ ID NO: 14))
targets the region of 83-99 nucleotides at the 3'end of pRNA.
P15 oligo (5'-AAGTACCGTACCATTGA (SEQ ID NO:
15)) targets the region of 1-17 nucleotides at the 5'end of
pRNA.
PS
oligo
(5'-TAATACGACTCACTATAGGGGTGGTAC-3' (SEQ ID NO: 16)) was designed
as a non-targeting control in the test. 1 µl of individual oligos
at 100 µM were mixed with 1 µl of pRNA at 4 µM and
dialyzed on a 0.025 µm type VS filter membrane (Millipore
Corp) against TBE buffer (89 mM Tris-HCl, pH 8.3, 89 mM
boric acid, 2.5 mM EDTA) at room temperature for 15 min.
The purified RNA complex was used for in vitro phi29
assembly assay.
In Vitro Phi29 Assembly Assay
Purified components were subjected to in vitro viral
assembly assay as described previously. Briefly, 10 µg of
purified procapsids were mixed with 100 ng of pRNA in 5
µl ofreaction buffer (10 mMATP, 6 mM 2-mercaptoethanol,
and 3 mM spermidine in TMS buffer) at room temperature
for 30 min. Purified DNA-gp3 and gp16 were then added
and the reaction mixture was incubated at room temperature
for one hour to initiate DNA packaging. Finally, the DNA
filled procapsids were incubated with 10 µl of gpS.5-9
extract from E. coli containing plasmid pARgpS.5-9 and 20
µl of gpl 1-14 extract from E. coli to complete the infectious
phage assembly.
The newly assembled infectious viruses were plated with
inoculated B. subtilis bacteria su+44 cells onto a half LB
plate covered with top agar. After 12 hour incubation at 37°
C., the viral assembly efficiency (plaque-forming unit, PFU)
was calculated by counting the formed plaque numbers.
Mixing different ratios of mutant with wild-type components, while keeping all other components the same, the
viral assembly efficiency (PFU) versus ratio of mutant
components gave an empirical curve for vial assembly
inhibition assay, and it was compared with theoretical curves
from the binomial distribution equation.

In Vivo Viral Assembly Assay
Plasmid pRBwtRNA containing the pRNA coding
sequence under T7 promoter was constructed by ligating the
fragment coding pRNA sequence and T7 promoter into
pRB381-L550 vector (modified and kindly provided by M.
Wang and H. Zalkin) following a previously described
method. Plasmid pRBmutRNA contained mutant pRNA
under its natural promoter PEI sequence, and the mutation
was changing sequence 5'UUGA-3' (SEQ ID NO: 17) at its
3'end to 5'GGGG-3'(SEQ ID NO: 18). The DNA fragments
coding mutant pRNA sequence and PEI sequence were
prepared by PCR as described previously; and digested with
HindIII-Bg!II restriction enzyme. The mutant pRNA
sequence coding fragment was further ligated with a 6.0 kb
fragment from pRB381-L550 that was digested with HindIII
and partially digested with Bg!II.
The plasmids pRBmutRNA, pRBmutRNA, and pRB381L550 were transformed into B. subtilis cells following
methods described previously. The B. subtilis cells harboring transformed plasmids were incubated in 416 medium
with 10 mg/ml of neomycin for 3 hours at 3 7° C. and then
plated onto LB-neomycin (10 mg/ml) plates for plaque
formation analysis.
Results
The Definition of "Stoichiometry".
The definition of the stoichiometry in this report is
different from conventional definition of stoichiometry used
to evaluate drug efficiency. Conventionally the concept of
stoichiometry refers to the number of a drug binding to each
target molecule, which is also known as Bmax· In this study
the definition of stoichiometry refers to the copy number of
subunit within a biocomplex or the nanomachine that serves
as drug target.
The Definition of "K Value", and K=l is One Key for
Ultra-High Inhibition Efficacy
Suppose a biocomplex drug target contains Z copies of
subunits, then K is the copy number (KsZ) of drugged
subunits required to inhibit the function of the complex or
the nanomachine. As an analogy to the difference between
the parallel circuit and the serial circuit, when the Christmas
lights are arranged in a parallel circuit, any light bulbs that
are burnt out will not affect other bulbs. But in a serial
circuit, any one light bulb that is broken will stop the entire
lighting system, which is K=l. Thus, the K value is the key
to the probability of inactive nanomachines or biocomplexes
by combination and permutation of all subunits. K equals 1
is critical for such ultra-high inhibition effect. The foundation of the approach in this report is the difference in
probability of inhibited biocomplexes in systems of different
K values with combination and permutation algorithms.
Biological systems display complicated reactions. Many
reactions involve multiple subunits to work cooperatively
sequentially or precessively to accomplish one essential
biological function. Single assembly pathways have been
reported in the viral assembly system. In most cases of the
sequential, cooperative, and processive action, inactivation
of any one, not necessary all, of the subunits will result in
inhibition of its function, thus K=l. Drug synergism was
utilized in multi-target drug therapy; in short, a drug combination can simultaneously act on multiple targets in disease networks to produce a synergistic effect. However, our
design reported here is unique from the conventional synergistic approach. We suggest that using multi-subunit biocomplexes as drug target could lead to development of
ultra-high potent drugs. In a conventional six-component
system, for example one drug is designed to target component #3 to stop the entire system, since the drug can only
target component #3, the condition fits the model of Z= 1 and
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K=l. Thus, the inhibition efficiency and substrate targeting
efficiency (p) of drug will be in linear relationship. However,
in the system in this report, the entire system will be blocked
when drug targets any subunit of a hexamer, which is Z=6
and K=l. Thus the probability of remaining undrugged
targets will be q 6 , where q represents the fraction of untargeted hexamer subunits; in other words, the drug inhibition
efficiency will be l-q 6 , which increases following a power
function compared to the linear for conventional monosubunit approaches.
Assuming that at least K copies of drugged subunits were
needed to deactivate the nanomachine or biocomplex, the
probability of functional biocomplexes in the presence of
various ratios of inhibited and wild-type subunits could be
predicted from equation 2. When K=l, it implies that drug
binding to one subunit will inactivate the subunit, and one
drugged subunit per multi-subunit complex is sufficient to
inhibit the overall function of the complex. The inhibition
efficiency by drugs targeting multi-subunit biocomplexes
with stoichiometry of Z will equal l-q2 , as shown in table
2. An example for such a probability calculation when Z=6
and K=l is as follows: since it was assumed that 6 (Z=6)
copies of subunits per element were required for function
and one drugged subunit (K=l) was sufficient to block its
activity, all elements possessing 1 to 5 copies of drugged
subunits would be non-functional (FIG. lC). Only those
complexes possessing 6 copies of normal subunits will be
functional. The chance for a complex containing 6 copies of
unaffected subunits in a population is q 6 and the inhibition
efficiency will be l-q 6 •
Rationale Behind Selection of Multi-Subunit Biocomplexes as Efficient Drug Targets
Mechanisms for drug inhibition of organism growth are to
block or stop an essential biological element from functioning. When a drug is designed to target the subunit of a
complex with targeting efficiency p, a fraction of subunits
will not interact with the drug (a percentile given as q,
p+q=l) and will remain active and exert their function
properly. Some biological elements are monomers containing only one subunit, while other biological elements, such
as the bin-motors of hexameric AAA+ family, consist of
multiple-subunits. Conventional drugs are designed to
inhibit pathogenesis through targeting of a single subunit
molecule, such as an enzyme or a structural protein of a
virus. In this situation, the inhibition efficiency is proportional to the substrate targeting efficiency p and the effect is
proportional to the first order of p. As described above, in
most cases of sequential action or cooperatives in multiple
subunit complexes, inactivation of one, not all, of the
subunits will result in inhibition of its function. Thus, if
complexes containing Z copies of subunits exercise their
function in a sequential and cooperative way, then K=l, and
the fraction of the uninhibited active biocomplex will be q
a higher order with regards to the stoichiometry. The inhibition proportion will equal l-q2 .
In this investigation, a well-defined in vitro phi29 viral
assembly system was used to represent a multi-subunit
nano-machine target, with the mutant component representing a target component that have been inactivated by an
effective drug. Then, the inhibition efficiencies by targeting
different elements of the phi29 DNA packaging motor with
different stoichiometry were compared. The viral assembly
competition assays combined with binomial distribution
analysis illustrated the concept that drug targeting functional
biological complexes of a higher-stoichiometry has a higher
efficiency than drug acting on a single subunit target.

When the target element is a monomer containing only
one subunit, the inhibition efficiency can be calculated
through a binomial distribution (equation 1), where p and q
are the fractions of drugged (substrate targeting efficiency)
and undrugged (normal active elements) subunits, respectively (p+q=l).
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However, when the target element contains multiple subunits, a high order binomial distribution (equation 2) is
applied to calculate the drug inhibition effect by finding the
ratio of resulted active and inactive complexes, where Z
represents the total number of subunits (the stoichiometry)
in one biocomplex and M represents the number of drugged
subunits in one biocomplex.
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Note that the binomial distribution as set forth in equation
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Computational results based on the binomial equation are set
forth herein. The context of the results governs which form
of the equation is used.
For example, if Z is 3, the probability of all combinations
of drugged subunits (M) and undrugged subunits (N;
M+N=Z) in a given biocomplex entity can be determined by
the expansion of equation 2: (p+q)3=p 3 +3p 2 q+3pq2 +q3 =1.
That is, the probability of a complex element possessing
three copies of drugged subunits in the population isp 3 , two
copies of drugged and one copy of undrugged or wild-type
subunit is 3p 2 q, one copy of drugged and two copies of
2
undrugged subunits is 3pq , and three copies of undrugged
subunits is q3 • Assuming there were 70% (p=0.7) of subunits
inactivated by bound drugs, and 30% (q=0.3) unaffected
subunits in the population, then the percentage of elements
possessing at least two copies of normal subunits would be
the sum of those possessing one copy of drugged and two
copies of undrugged wild-type subunits, 3pq2 , and those
possessing three copies of native subunits is q 3 • That is
3pq2 +q3 =3(0.7)(0.3)+(0.3)3=0.216=21.6%.
In
another
example, if one complex contains 6 subunits, and 5 out of
the 6 subunits need to remain uninhibited in order to be
biologically functional, the active complex ratio in the
population will be the sum of: 1) the probability of each
element containing 5 undrugged subunits, and 2) the probability of each element containing 6 undrugged subunits.
The probability X in the population displaying a certain
combination of undrugged versus drugged subunits can be
predicted by a binomial distribution, as shown in equation 2.
Table 1 shows the probability of a given element with M
drugged and N undrugged subunits at increasing percentages
of drugged subunits in the population, considering that the
total subunits in one element (Z) is 3 or 12. The formula,
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(from equation 2) was used to calculate each combination
probability value, the coefficient

was constructed by mutating 4 nucleotide sequences at the
5'end region of pRNA (FIG. 14A, lower panel), which has
been shown to compete with wild-type pRNA for procapsid
binding, but was found to be deficient in allowing DNA
packaging to occur. The theoretical curves generated using
the expansion of binomial distribution equation while total
subunit number Z is 6 and varying K number from 1 to 6 are
shown in FIG. 14B. Fitting the empirical data from phage
assembly efficiency at different ratios of drugged mutant
pRNAs into the theoretical curves, the empirical data fit into
the theoretical curve of Z=6 and K=l. It suggested that the
pRNA oligomer ring is composed of six copies of pRNA
subunits and one subunit of the pRNA multimer blockage is
sufficient to block the phage assembly activity. Comparing
the empirical curve for viral assembly efficiency against
different ratios of drugged mutant pRNAs with the wild-type
pRNA concentration dilution control, addition of drugged
mutant pRNA showed a much stronger inhibition effect
(FIG. 3C).
To further prove the concept that drugs targeting biocomplex with high stoichiometry causes stronger inhibition
effect, antisense oligonucleotides which can bind to pRNA
molecules were designed as mock drugs in the viral assembly assay. The oligonucleotides P15, and P3 were designed
to target the 5'-end and 3'-end regions on pRNA, respectively. It was confirmed that the antisense oligonucleotides
can be hybridized to pRNA by gel shift assay (data not
shown). When mixing the antisense oligonucleotides with
wild-type pRNA for in vitro phi29 assembly assay, complete
inhibition effects were shown by antisense oligonucleotides
P15, and P3, but not with the non-targeting control oligonucleotide PS. By mixing the non-targeting oligo PS with
pRNA, it generated plaques with 4.4xl0 6 PFU on the plate.
In Vivo Testing of the Hypothesis Using RNA Elements
with Stoichiometry of 6
Formation of the hexameric ring of pRNA in the phi29
dsDNA packaging motor has been discovered through biochemical and structural studies and activity assays. The
observed high inhibition efficiency by drugged mutant
pRNA on phi29 assembly in vitro was striking. To test
whether such a high level of inhibition was attainable in
vivo, pRBmutRNA plasmid expressing a pRNA with 4-base
mutation at the 3' end (FIG. 15A) was transformed into B.
subtilis DEi cells. Plasmid pRBwtRNA contained the
pRNA coding sequence but do not express pRNA in B.
subtilis DEi cells, and vector pRB3Sl-L550 was introduced
as well as a negative control. The results showed that only
cells harboring pRBmutRNA plasmid were completely
resistant to plaque formation by wild-type phi29 virus
infection. Control cells, includingB. subtilis 12Acells alone,
B. subtilis DEi cells carrying vector pRB3Sl-L550 alone,
and cells carrying a wild-type pRNA coding sequence but no
expression plasmid pRBwtRNA were all positive for plaque
fin (nation (FIG. 15B). The ability of mutant pRNAs generated in cells by plasmid pRBmutRNA completely inhibited plaque formation indicated that hexameric pRNA in
DNA packaging nano-motor may be a potential target for
developing potent antiviral agents.
In Vitro Testing of the Hypothesis Using theATPase with
Stoichiometry of 6
Hexameric folding of ATPase gp16 protein in the phi29
dsDNA packaging motor has been discovered. The hexameric gp16 protein complex functions as ATPase like many
other AAA+ superfamily members. ATP binding to one
subunit of gpl 6 stimulates the ATPase to change its conformation from having a lower affinity to one having a higher
affinity for dsDNA.
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in this equation can also be calculated using Yang Hui
Triangle, which is also called Pascal's Triangle, or binomial
distribution (FIG. 12B).
In Vitro Virus Assembly System Used for Testing the
Hypothesis
The highly sensitive in vitro phi29 assembly system was
used to determine the inhibition efficiency of drugs targeting
multi-subunit complexes. Bacteriophage phi29 DNA packaging motor contains one copy of genomic dsDNA, 6 copies
of packaging RNA, 6 copies of ATPase protein gp16 and
more than 10000 copies of ATP. The stoichiometry of RNA
in phi29 has been proven by extensive studies including
single-molecule studies AFM images (FIG. lD), pRNA
crystal structure determination (FIG. lE), and mathematical
studies. The stoichiometry of gpl 6 in phi29 has been proven
by multiple approaches including native gel binding, capillary electrophoresis assays, Hill constant determination, and
by titration of mutant subunits using binomial distribution.
Many other AAA+ superfamily members have been found to
be hexamers as well, such as a red type rubisco activase
AAA+ protein CbbX (FIG. 12F), MecA-ClpC molecular
machine (FIG. 12G). The copy number of ATP molecules
was calculated based on the fact that 6 ATP molecules are
required to package one pitch of dsDNA with 10.5 basepairs
(hp), thus 1 ATP is used to package 1.7 bp. The entire phi29
genome is composed of 19.4 kbp, thus, it is expected that
more than 10000 ATP molecules are required to package the
entire phi29 genome. The phi29 DNA nano-motor which
packages an entire genomic DNA into the procapsid can be
treated as a disease model for drug inhibition efficiency
analysis.
In Vitro Testing of the Hypothesis Using DNA Element
with Stoichiometry of 1
The inhibition efficiency of drugs targeting a single subunit substrate was tested by in vitro phi29 assembly inhibition by mutating the genomic dsDNA (FIG. 13A). Various
ratios of mutant DNA were mixed with wild-type DNA in in
vitro viral assembly assays. The empirical curve of viral
assembly efficiency against drugged mutant DNA ratio fits
well with the theoretical curve from binomial distribution
for Z=l and K=l (FIG. 13B). This suggests that when
designing drug targeting the genomic DNA in phi29 nanomotor, it is expected to be a first order inhibition response.
Comparing the in vitro phi29 assembly inhibition, by adding
drugged mutant DNA, with simply diluting wild-type DNA
concentration as a control, revealed that the drugged mutant
DNA didn't cause much difference (FIG. 13C). The results
showed that the inhibition effect of drugs targeting the
substrate with stoichiometry of 1 is minimal.
In Vitro Testing of the Hypothesis Using RNA Elements
with Stoichiometry of 6
The pRNA of phi29 contains two domains; a head-loop
domain essential for procapsid binding and a helix domain
essential for DNA translocation (FIG. 14A, upper panel).
The right-hand loop and left-hand loop of two pairing pRNA
molecules can interact with each other by complementary
base pairing. Extensive studies have led to the conclusion
that 6 copies of pRNA form a hexameric ring which binds
to the procapsid for virus activity. Drugged mutant pRNA
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Determination of gp16 stoichiometry was carried out by
in vitro phage assembly assay and based on the binomial
distribution of wild-type and Walker B mutant gp16. Different ratios of drugged Walker B mutant gp16 were mixed
with undrugged gp16 to test the inhibition efficiency of gp16
mutation on phi29 DNA packaging motor. Assuming K
equals 1 and the total copy number of gp16 (Z) is between
1 and 12, twelve theoretical curves for the production of
phi29 virion against the ratio of the Walker B mutant
corresponding to the stoichiometry (Z) of 1 to 12 were
generated according to equation 2. The empirical data nearly
perfectly overlapped the theoretical curve of Z=6, K = 1. This
data suggested that the ATPase gpl 6 components of phi29
DNA packaging motor have a stoichiometry of six, and only
one copy of the drugged gp16 can block the phi29 motor
function. Comparing the inhibition effect of adding mutant
gp16 with wild-type gp16 at different concentrations, it
showed that adding mutant gp16 had a much stronger
inhibition effect than the wild-type gp16 concentration dilution control (FIG. 16A). Comparing the inhibition effect of
mutation on hexameric gp16 to the effect of mutation on
single subunit target DNA, the gp16 mutation displayed a
much stronger inhibition effect on virus assembly than the
same ratio of DNA mutation, indicating the hexameric
ATPase protein complex of virus assembly system should
also be an efficient target for generating new anti-virus drugs
with high potency.
In Vitro Testing of the Hypothesis Using ATP with Stoichiometry of More than 10000
It has been reported that 6 ATP molecules are required to
package one pitch of dsDNA with 10.5 bp [90], thus 1 ATP
is used to package 1.7 bp. As the entire phi29 genomic DNA
has 19,000 base pairs, it is expected that more than 10000
ATP molecules are required to package the entire phi29
genome. Since concerning ATP, the functional unit displayed
in FIG. 5 is the viral production expressed as plaque-forming
unit (PFU), so the production of one functional unit of PFU
require 10000 ATP subunits to package one genomic DNA.
Thus, the ATP in one phi29 nanomotor can be regarded as a
stoichiometry of 10000. One non-hydrolysable ATP analogue y-S-ATP was treated as the drugged subunit that mixed
with ATP at different ratios to test the inhibition effect of
y-S-ATP on phi29 assembly efficiency. It was found that the
inhibition curve of mutant ATP fits into the theoretical curve
between Z=l00, K=l and Z=60, K=l (FIG. 16B). The
empirical ATP value derived from binomial distribution
assay was different from real condition, since the binomial
distribution equation was based on a condition that each
subunits has the same binding affinity to the biocomplex in
the targetednanomotor, but due to the change of the y-S-ATP
structure, it has a ATPase gp16 binding affinity lower than
the normal ATP. Furthermore, the affinity difference in each
subunit has a multiplicative effect in the nanomotor's activity. Thus, there is a big discrepancy between the curves with
predicted Z value and the empirical Z value.
Comparing virus assembly inhibition effect using different components, the y-S-ATP showed a severe inhibition
effect (FIG. 16C). Adding 20% of gamma-s-ATP nearly
completely inhibited the viral assembly. Comparing the
inhibition effect targeting to ATP, pRNA, ATPase gpl 6, and
DNA with stoichiometry of 10000, 6, 6, and 1, respectively,
y-S-ATP showed the strongest inhibition effect, while
drugged mutant pRNA and mutant gp16 showed stronger
inhibitory effect than mutant DNA (FIG. SC). For example,
adding 20% mutant DNA caused 20% inhibition effect in
viral assembly, while 20% of drugged mutant pRNA exerted
74% of inhibition effect on viral assembly and 20% of

y-S-ATP almost completely inhibited the viral assembly,
indicating the higher the stoichiometry, the stronger the
inhibition efficacy.
Mathematical Reasoning for the Increase of Inhibition
Efficacy
Using a biological complex with higher stoichiometry as
drug target will substantially reduce the proportion of noninhibited complex. For K=l, the proportion of non-inhibited
complex is q2 . Table 3 compares the proportion of noninhibited complex from two populations with Z=6 and Z=l,
respectively, with varied substrate targeting efficiency (p)
when K=l. For example, when q=0.4, the proportion of
non-inhibited complex is q2 =0.4 1 =0.4 for Z=l K=l. Therefore, only 1-0.4=60% of complex is inhibited. In contrast,
for Z=6, K=l, the proportion of non-inhibited complex is
q2 =0.4 6=0.0041. Therefore, 1-0.0041=99.59% of complex
is inhibited. The ratio of the proportions of non-inhibited
complex
equals
0.0041/0.4=0.0102,
indicating
a
1/0.0102=98-fold decrease in the proportion of non-inhibited complex. One more example is to use the drug targeting
efficiency p=0.9 to compare the inhibition efficiency
between two groups with Z=6 and Z=l. For Z=6, K=l, the
proportion of inhibited complex is l-q2 =1-0.l 6=0.999999.
The proportion of non-inhibited complex is q2 =0.1 6=1E-6.
For Z=l, K=l, the proportion of inhibited complex is
l-q2 =1-0.1 =0.9. The proportion of non-inhibited complex is
q2 =0.1. The ratio of inhibition efficiency equals to lE-6/
0.l=lE-5, indicating a 10000-fold increase in inhibition
efficiency (Table 3).
The equation displays inhibitory effect with a power
function of stoichiometry since when K = 1, the percentage of
uninhibited biocomplexes in the population equal to q
Since (P+q)=l, thus qsl, thus the larger the Z, the smaller
the value of q That is to say, the higher the stoichiometry,
the smaller number of the uninhibited background will
display. With the same substrate targeting efficacy, p, the
inhibition efficiency is determined by z, the power of the
equation component. The inhibitory effect is a power function concerning the stoichiometry. Thus, the higher the
stoichiometry, the more efficient the inhibition comparing
the drugs with same binding affinity.
The half maximal inhibitory concentration (IC 50 ) is commonly used to evaluate drug effect, which quantitatively
indicates how much of a particular drug is needed to inhibit
a given biological process by half. Ifwe denote Picso as the
percentage of drugged subunit needed to reach to 50%
inhibition in the in vitro assay in the defined system, thus
l-(1-Picsof=50%. Solving this equation, Picso=l-0.5 112.
FIG. 17 shows the relationship between stoichiometry (Z)
and drug targeting level p to reach the inhibition effect (IC),
where p is the combined result of drug binding efficacy and
drug concentration (dosage). When biocomplexes with stoichiometry of Z are used as drug targets, the dosage of drug
or the drug binding affinity presented by percentage of
drugged subunits to reach IC 50 , IC 25 , or IC 75 decreases. This
clearly shows that as Z increases, decreases (FIG. 17), and
hence the drug is more potent.
Discussion
Aiming to find a method for developing drugs with
ultra-high potency, we proposed that the inhibition efficiency of a given drug depends on stoichiometry of the
biocomplex or bio-machine that was used as drug target.
Here the definition of the stoichiometry is different from
conventional definition of stoichiometry used to evaluate
drug efficiency. Conventional thinking in drug development
emphasizes stoichiometry which refers to the number of
drug binding per target molecule, which is also known as
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In this study the definition of stoichiometry refers to
the copy number of subunit within a biocomplex that serves
as drug target. We used phi29 viral components with a series
of variable but known stoichiometry as mock drug targets to
test the hypothesis. Both in vitro and in vivo won assembly
assays were employed to compare the inhibition efficiency
targeting to components with different numbers of subunit
stoichiometry. Viral inhibition efficiency was analyzed with
Yang Hui's (Pascal's) Triangle (or knowns as binomial
distribution). It was found that inhibition efficiency on virus
replication correlates to the component stoichiometry of
nano-machine as drug target. It displayed power law inhibitory effect since when K=l, the percentage of uninhibited
biocomplexes in the population equal to q With the same
q and same K value, the inhibition efficiency is determined
by z, the number of subunits within the biocomplex or the
bio-machine as drug target. Here z serves as the power in the
equation, thus, the inhibitory effect is the power of the
stoichiometry. Empirical data demonstrated that the target
with thousand-subunits shows higher inhibition effect than
the targets with six subunits, and in turn higher than the
target with single subunit.
In evaluation of drug effect, two parameters were commonly used. One is the half maximal inhibitory concentration (IC 50 ), which quantitatively indicates how much of a
particular drug is needed to inhibit a given biological
process by half. It is universally used as a measure of drug
potency in pharmacological research. Another important
parameter is the median lethal dose (LD 50 ), which is also
known as 50% of lethal concentration (LC 50 ). LD 50 is
frequently used to indicate a substance's acute toxicity.
Obviously, the usefulness of a drug will dependent on the
ratio of LD 50 to IC50 . The larger this ratio, the safer the drug.
By ways of increasing the inhibition efficiency through
targeting to the components with high stoichiometry, the
IC 50 of a drug will decrease. As a result, lower concentration
of drug will be required for reaching a desired effect,
resulting in a reduced toxicity of the drug.
Most of current anti-cancer, anti-virus or anti-bacteria
drugs target single enzymes or single proteins. Our data
showed that drugs selected to target components, biocomplexes, or nano-machines with high copy numbers could
lead to a much higher efficacy, and it could potentially solve
the problem of low drug effect and multi-drug resistance.
Conclusions
Targeting the functional biological units with higher stoichiometries will have a higher efficiency of inhibition. The
inhibition effect is power, other than proportional, and the
power, is the copy number of the drug-targeted element of
the machine. The new theory developed herein suggests that
potent drugs can be developed by targeting biocomplex with
high stoichiometry, and a complete inhibition of virus,
bacterium, or cancer is possible if a bio-machine with high
stoichiometry is identified. Since bio-motors share certain
common structure and operation mechanism in viruses,
bacteria, and cells, approach should have getter-application
in drug development.
Future Perspective
Living systems contain many elegant arrays, motors and
nanomachines that are multi-subunit complex. As reported
here, these biocomplex with high copy number of components can serve as potent drug targets. For example, most
members of the AAA+ family are hexamer. However, these
machines are common in living systems therefore the specificity and toxicity is an issue. For bacteria and virus, since
our goal is to kill them nonexclusively, the specificity and
toxicity is not an issue as long as the target biocomplex is not

identical to that in human body. For cancers drugs, as long
as a mutation is found in the multiple-subunit biocomplex,
it will be an ideal target for potent drug.
Executive Summary
Aim
A method for developing potent drugs is sought.
Without being bound by theory, drug inhibition potency
depends on the stoichiometry of the targeted biocomplex.
Approach:
Phi29 viral components with variable stoichiometry were
used as model to prove the hypothesis
Virion assembly efficiency was assayed and analyzed with
Yang Hui's Triangle:

Bmax·
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Results:
Inhibition efficiency displayed a power function of the
stoichiometry of the target biocomplexes. The uninhibited
biocomplex in population can equals to q Thus, the inhibitory effect is a power of the stoichiometry.
Targets with thousand-subunit showed higher inhibition
effect than with six subunits, and in tum higher than target
with single subunit.
A complete inhibition of virus, bacterium, or cancer was
demonstrated when targets with high stoichiometry was
used as target.
Conclusion:
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Drug inhibition potency depends on the stoichiometry of
the targeted components of the biocomplex or nano-machine.
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The inhibition effect displayed a power function of the
stoichiometry of the target biocomplex.
Since bio-motors share certain common structure and
operation mechanism in viruses, bacteria, and cells, this
approach should have general application in drug development.
Finally, for further explanation of the features, benefits
and advantages of the present invention, attached hereto is
Appendices A-F, which are incorporated herein by this
reference in their entirety, as are all cited references in
Appendices A-F.
The following two publications (set forth in paragraphs
00295 and 00296 below) are herein incorporated by reference in their entirety.
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New approach to develop ultra-high inhibitory drug using
the power function of the stoichiometry of the targeted
nanomachine or biocomplex. Publication J and date: Nanomedicine (Land). 2015 July; 10(12):1881-97. doi: 10.2217/
nmn.15.37.
Discovery of a new method for potent drug development
using power function of stoichiometry of homomeric biocomplexes or biological nanomotors. Publication J and date:
Expert Opin Drug Deliv. 2016 January; 13(1):23-36.
All publications, patents, and patent applications mentioned in this specification, including those set forth in the
following list, are herein incorporated by reference to the
same extent as if each individual publication, patent, or
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APPENDIX B
Tables in this Appendix Correspond to the Tables
Set Forth in Section 1
TABLE 1

Probability of the complex containing M copies of drugged subunits and N copies of undrugged subunits
Inhibited

Z - 3

Subunits (p)

M - 0, N - 3

M -1, N-2

M- 2, N- 1

M - 3, N- 0

0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9

1.0000
0.7290
0.5120
0.3430
0.2160
0.1250
0.0640
0.0270
0.0080
0.0010
0.0000

0.0000
0.2430
0.3840
0.4410
0.4320
0.3750
0.2880
0.1890
0.0960
0.0270
0.0000

0.0000
0.0270
0.0960
0.1890
0.2880
0.3750
0.4320
0.4410
0.3840
0.2430
0.0000

0.0000
0.0010
0.0080
0.0270
0.0640
0.1250
0.2160
0.3430
0.5120
0.7290
1.0000

Inhibited

Z - 12

Subunits
(p)

M - 0,
N-12

M-1,
N - 11

M -2,
N-10

M- 3,
N- 9

M-4,
N- 8

M - 5,
N- 7

M- 6,
N- 6

M -7,
N- 5

M- 8,
N-4

M -9,
N-3

0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9

1.0000
0.2824
0.0687
0.0138
0.0022
0.0002
0.0000
0.0000
0.0000
0.0000
0.0000

0.0000
0.3766
0.2062
0.0712
0.0174
0.0029
0.0003
0.0000
0.0000
0.0000
0.0000

0.0000
0.2301
0.2835
0.1678
0.0639
0.0161
0.0025
0.0002
0.0000
0.0000
0.0000

0.0000
0.0852
0.2362
0.2397
0.1419
0.0537
0.0125
0.0015
0.0001
0.0000
0.0000

0.0000
0.0213
0.1329
0.2311
0.2128
0.1208
0.0420
0.0078
0.0005
0.0000
0.0000

0.0000
0.0038
0.0532
0.1585
0.2270
0.1934
0.1009
0.0291
0.0033
0.0000
0.0000

0.0000
0.0005
0.0155
0.0792
0.1766
0.2256
0.1766
0.0792
0.0155
0.0005
0.0000

0.0000
0.0000
0.0033
0.0291
0.1009
0.1934
0.2270
0.1585
0.0532
0.0038
0.0000

0.0000
0.0000
0.0005
0.0078
0.0420
0.1208
0.2128
0.2311
0.1329
0.0213
0.0000

0.0000
0.0000
0.0001
0.0015
0.0125
0.0537
0.1419
0.2397
0.2362
0.0852
0.0000

TABLE 2
Predicted inhibition efficiency of drugs targeting biocomplexes, K - 1
Inhibition efficiency of the multi-subunit complex with

Drugged

subunit (p)

Z-1

Z-2

Z-3

Z-6

Z - 10

Z - 100

Z - 1000

0

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.1

0.1000

0.1900

0.2710

0.4686

0.6513

1.0000

1.0000

0.2

0.2000

0.3600

0.4880

0.7379

0.8926

1.0000

1.0000

0.3

0.3000

0.5100

0.6570

0.8824

0.9718

1.0000

1.0000

0.4

0.4000

0.6400

0.7840

0.9533

0.9940

1.0000

1.0000

0.5

0.5000

0.7500

0.8750

0.9844

0.9990

1.0000

1.0000

0.6

0.6000

0.8400

0.9360

0.9959

0.9999

1.0000

1.0000

0.7

0.7000

0.9100

0.9730

0.9993

1.0000

1.0000

1.0000

0.8

0.8000

0.9600

0.9920

0.9999

1.0000

1.0000

1.0000

0.9

0.9000

0.9900

0.9990

1.0000

1.0000

1.0000

1.0000

1.0000

1.0000

1.0000

1.0000

1.0000

1.0000

1.0000

M -10, M -11, M- 12,
N- 2
N-1
N- 0
0.0000
0.0000
0.0000
0.0002
0.0025
0.0161
0.0639
0.1678
0.2835
0.2301
0.0000

0.0000
0.0000
0.0000
0.0000
0.0003
0.0029
0.0174
0.0712
0.2062
0.3766
0.0000

0.0000
0.0000
0.0000
0.0000
0.0000
0.0002
0.0022
0.0138
0.0687
0.2824
1.0000
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TABLE 3

Comparison of proportion of non-inhibited complex between Z - 6 and
Z - 1 when K - 1 but having equal drug targeting efficacy

Substrate
targeting
efficacy
(p)

Proportion of noninhibited complex
from the population
with Z - 6

Proportion of noninhibited complex
from the population
with Z - 1

Ratio of the
proportions of noninhibited complex
from the two
populations
with Z - 6 and Z - 1

0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9

0.5314
0.2621
0.1176
0.0467
0.0156
0.0041
7E-04
lE-04
lE-06

0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1

0.5905
0.3277
0.1681
0.0778
0.0312
0.0102
0.0024
0.0003
lE-05

Reduction (fold) in
proportion of
non-inhibited complex
comparing
Z-6andZ-1

3.1
5.9
12.9
32
98
416
3333
10000

1.7
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APPENDIX C
This Appendix Provides Synopses for Certain
References Set Forth in Appendix A
25

1**. Guo P, Zhao Z, Haak J, Wang S, Weitao T. Common
Mechanisms of DNA translocation motors in Bacteria and
Viruses Using One-way Revolution Mechanism without
Rotation. Biotechnology Advances. 32, 853-872 (2014).
Synopsis: This review reports that revolution mechanism is
commonly used in bacteria and viruses which avoid DNA
g in translocation the lengthy genomic dsDNA helix.
19*. Schwartz C, De Donatis GM, F ng H, Guo P. The
ATPase of the phi29 DNA-packaging motor is a member
of the hexameric AAA+ superfamily. Virology 443, 20-27
(2013).
Synopsis: This paper confirmed the stoichiometry of ATPase
in phi29 motor is a hexamer and provided data suggesting
that the phi29 motor ATPase belongs to classical hexameric AAA+ superfamily.
33*. Schwartz C, Donatis GM, Zhang H, Fang H, Guo P.
Revolution rather than rotation of AAA+ hexameric phi29
nanomotor for dsDNA packaging without coiling. Virology 443, 28-39 (2013).
Synopsis: This paper shows how the nanomotor in phi29
virus w with a revolution mechanism using six copies of
ATPase.
36**. De-Donatis G, Zhao Z, Wang S et al. Finding of
widespread viral and bacterial revolution dsDNA translocation motors distinct from rotation motors by channel
chirality and size. Cell & Bioscience 4, 30 (2014).
Synopsis: This paper reports that the revolution motor
nanomachine is widespread among biological systems, an
can be distinguished from rotation motors by channel size
and chirality.
51 **. Fang H, Huang LP et al. Binomial distribution for
quantification of protein subunits in biological nanoassemblies and functional nanomachines. Nanomedicine.
10(7), 1433-40 (2014).
Synopsis: This is the first report to describe how to use the
Yang Hui's Triangle (binomial distribution to determine
the stoichiometry of protein subunits in biocomplex. It
precisely confirmed that phi29 motor contains six copies
of ATPase gp16 and one mutant subunit would cause
motor to stop.
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52*. Gun P. Zhang C, Chen C, Trottier M. Garver K. Inter-I
interaction of phage phi29 pRNA to form a hexameric
complex for viral DNA transportation. Mal. Cell. 2,
149-15, (1998
Synopsis: This is the first paper to reveal that the pRNA of
phi29 DNA packaging motorfirms a hexameric ring, and
prove-of-concept of RNA nanotechnology since this
paper shows that by bottom-up assembly, the RNA nanoparticles of dimers, trimers and hexamers can be constructed using the reenginered RNA fragments derived
from phi29 motor pRNA.
*56. Trottier M, Quo P. Approaches to determine stoichiometry of viral assembly components. J. Viral. 71, 487494 (1997),
Synopsis: This is the first report to describe how to use the
Yang Hui Triangle (binomial distribution) to determine
the stoichiometry of biocomplex or nanomachine.
81 *. Shu D, Zhang H, Guo P. Counting of six pRNAs of
phi29 DNA-packaging motor with customized single
molecule dual-view system. EMBO J. 26, 527-537
(2007).
Synopsis: This is the first report describing the use of single
fluorophore photobleaching technique to count subunits
in biocomplex, and documents the "seeing is believing" to
confirm that phi29 DNA packaging motor contains six
copies of packaging pRNA.
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APPENDIX E
Tables in this Appendix Correspond to the Tables
Set Forth in Paragraphs Section 2
Z -1

Z - 6

Inhibited
Subunits (p)

M - 0,
N-1

M-1,
N-0

M -0,
N- 6

M-1,
N- 5

M -2,
N-4

M - 3,
N- 3

M-4,
N-2

M -5,
N-1

M- 6,
N- 0

0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

0%
9%
16%
21%
24%
25%
24%
21%
16%
9%
0%

100%
53%
26%
12%
5%
2%
0%
0%
0%
0%
0%

0%
35%
39%
30%
19%
9%
4%
1%
0%
0%
0%

0%
10%
25%
32%
31%
23%
14%
6%
2%
0%
0%

0%
1%
8%
19%
28%
31%
28%
19%
8%
1%
0%

0%
0%
2%
6%
14%
23%
31%
32%
25%
10%
0%

0%
0%
0%
1%
4%
9%
19%
30%
39%
35%
0%

0%
0%
0%
0%
0%
2%
5%
12%
26%
53%
100%

APPENDIX F
Tables in this Appendix Correspond to the Tables
Set Forth in Paragraphs Section 3

25

TABLE 1
Z-3

Inhibited

Z - 12

Subunits

M - 0,

M-1,

M -2,

M- 3,

M- 0,

M-1,

M- 2,

M -3,

M-4,

(p)

N- 3

N- 2

N-1

N- 0

N- 12

N- 11

N- 10

N- 9

N- 8

0

1.0000

0.0000

0.0000

0.0000

1.0000

0.0000

0.0000

0.0000

0.0000

0.1

0.7290

0.2430

0.0270

0.0010

0.2824

0.3766

0.2301

0.0652

0.0219

0.2

0.5120

0.3840

0.0960

0.0080

0.0687

0.2062

0.2835

0.2362

0.1329

0.3

0.3430

0.4410

0.1890

0.0270

0.0138

0.0712

0.1678

0.2397

0.2311

0.4

0.2160

0.4320

0.2880

0.0640

0.0022

0.0174

0.0619

0.1419

0.2128

0.5

0.1250

0.3750

0.3750

0.1250

0.0002

0.0029

0.0161

0.0537

0.1208

0.6

0.0640

0.2880

0.4320

0.2160

0.0000

0.0003

0.0025

0.0125

0.0420

0.7

0.0270

0.1890

0.4410

0.3430

0.0000

0.0000

0.0002

0.0015

0.0078

0.8

0.0080

0.0960

0.3540

0.5120

0.0000

0.0000

0.0000

0.0001

0.0005

0.9

0.0010

0.0270

0.2430

0.7290

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

1.0000

0.0000

0.0000

0.0000

0.0000

0.0000

Inhibited

Z - 12

Subunits

M- 5,

M - 6,

M- 7,

M- 8,

M - 9,

(p)

N- 7

N- 6

N- 5

N-4

N- 3

N-2

N-1

N- 0

0

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.1

0.0038

0.0005

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.2

0.0532

0.0155

0.0033

0.0005

0.0001

0.0000

0.0000

0.0000

0.3

0.1585

0.0792

0.0291

0.0078

0.0015

0.0002

0.0000

0.0000

0.4

0.2270

0.1766

0.1009

0.0420

0.0125

0.0025

0.0003

0.0000

0.5

0.1934

0.2256

0.1934

0.1208

0.0537

0.0161

0.0029

0.0002

0.6

0.1009

0.1766

0.2270

0.2128

0.1419

0.0639

0.0174

0.0022

0.7

0.0291

0.0792

0.1585

0.2311

0.2397

0.1678

0.0712

0.0138

0.8

0.0033

0.0155

0.0532

0.1329

0.2362

0.2835

0.2062

0.0687

0.9

0.0000

0.0005

0.0038

0.0213

0.0832

0.2301

0.3766

0.2524

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

0.0000

1.0000

M - 10, M - 11, M - 12,
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TABLE 2
Predicted inhibition efficiency of drugs targeting biocom12lexes: K = 1
Inhibition efficiency of the multi-subunit com12lex with

Drugged
subunit (p)

Z-1

Z-2

Z-3

Z-6

Z - 10

Z - 100

Z - 1000

0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9

0.0000
0.1000
0.2000
0.3000
0.4000
0.5000
0.6000
0.7000
0.8000
0.9000
1.0000

0.0000
0.1900
0.3600
0.5100
0.6400
0.7500
0.8400
0.9100
0.9600
0.9900
1.0000

0.0000
0.2710
0.4880
0.6570
0.7840
0.8750
0.9360
0.9730
0.9920
0.9990
1.0000

0.0000
0.4686
0.7379
0.8824
0.9533
0.9844
0.9959
0.9993
0.9999
1.0000
1.0000

0.0000
0.6513
0.8926
0.9718
0.9940
0.9990
0.9999
1.0000
1.0000
1.0000
1.0000

0.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000

0.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000

TABLE 3
Comparison of proportion of non-inhibited complex between Z - 6 and
Z - 1 when K - 1 but having equal drug targeting efficacy
Ratio of the
proportions of non-

Substrate
targeting
efficacy
(p)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9

Proportion of non-

Proportion of non-

inhibited complex
inhibited complex
from the population from the population
with Z - 6
with Z - 1

0.5314
0.2621
0.1176
0.0467
0.0156
0.0041
7E-04
lE-04
lE-06

0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1

inhibited complex
from the two
populations
with Z - 6 and Z - 1

0.5905
0.3277
0.1681
0.0778
0.0312
0.0102
0.0024
0.0003
lE-05

What is claimed is:
1. A method for the identification of multi-subunit biocomplex drug targets, the method comprising,
identifying a target that performs a biological function,
wherein the target comprises one or more subunits,
wherein a minimum number (K) of the one or more
subunits is inactivated (M) to inhibit the biological
function;
selecting a drug that binds specifically to each subunit of
the one or more subunits with a target probability (p),
wherein the target probability comprises a common
probability for each subunit that the drug delivered to
the target inactivates the subunit;
describing a relationship between inhibition efficiency of
the drug and total number (Z) of the one or more
subunits using a binomial distribution, wherein the
inhibition efficiency comprises a probability that the
delivered drug blocks the biological function, wherein
the inhibition efficiency is computed with respect to the
minimum number and the total number;
confirming empirically the relationship using an experimental target, wherein the target includes the experimental target;
administering the drug to the target to treat a multi-drug
resistant disease, wherein the target comprises a biological complex in a mammalian subject.

Reduction (fold) in
proportion of
non-inhibited complex
comparing

Z-6andZ-1

1.7

3.1
5.9
12.9
32
98
416
3333
10000
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2. The method of claim 1, wherein variable N represents
an active subunit of the one or more subunits, wherein
Z=M+N.
3. The method of claim 1, wherein q=l-p.

45

4. The method of claim 3, wherein a probability that the
target includes M inactivated subunits and N active units is
given by the binomial expression

50
(Z!)
(N!)(M!)p

55
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MN

q.

5. The method of claim 4, wherein the inhibition efficiency is given by the binomial equation

~(

U

Z!
) Mc/'-M
M!(Z-M)! p
.

M=l

65

6. The method of claim 5, wherein K=l and Z>l.
7. The method of claim 6, wherein the inhibition effi2

ciency is given by l-q

•
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8. The method of claim 1, wherein the experimental target

identifyi1;1g a target that performs a biological function,
wherem the target comprises one or more subunits,
comprises a component or subunit of a multimeric biocomwherein a minimum number of the one or more subplex or a biological nanomotor.
units is inactivated to inhibit the biological function·
9. The method of claim 8, wherein the nanomotor comselecting
a drug that binds specifically to each subunit ~f
prises a linear motor, a rotation motor, or a revolution motor. 5
the one or more subunits with a target probability,
10. The method of claim 8, wherein the nanomotor
wherein the target probability comprises a common
comprises an ATPase component.
probability for each subunit that the drug delivered to
11. The method of claim 8, wherein the multimeric
the
target inactivates the subunit;
biocomplex comprises a receptor, a channel, an enzyme, or
describing a relationship between inhibition efficiency of
a transporter.
1o
the drug and total number of the one or more subunits
12. The method of claim 8, wherein the multimeric
using a binomial distribution, wherein the inhibition
biocomplex comprises a homomeric biocomplex.
efficiency comprises a probability that the delivered
13. The method of claim 8, wherein the multimeric
drug blocks the biological function, wherein the inhibiocomp_lex comprises a dimer, a hetero-oligomer, or a
bition
efficiency is computed with respect to the minihomo-ohgomer.
15
mum number and the total number;
14. The method of claim 8, wherein the number of
confirming empirically the relationship using an expericomponents or subunits is at least 2 3 4 5 6 7 8 9 10
mental target, wherein the target includes the experi11, or 12.
' ' ' ' ' ' ' '
'
mental target;
15. The method of claim 8, wherein the nanomotor is a
administering the drug to the target to treat a multi-drug
bacteriophage Phi29 DNA packaging motor.
20
resistant disease, wherein the target comprises a bio~6. The method of claim 15, wherein the bacteriophage
logical complex in a mammalian subject.
Phi29 DNA packaging motor comprises a genomic dsDNA
25.
A method for treating a subject afflicted with a
component, a packaging RNA component, an ATPase gp 16
multi-drug resistant disease, the method comprising,
component, an ATP component, or a combination thereof.
identifying a target that performs a biological function,
17. The method of claim 16, wherein each Phi29 DNA 25
wherein the target comprises one or more subunits,
packaging motor component comprises the experimental
wherein a minimum number of the one or more subtarget.
units is inactivated to inhibit the biological function;
~8. The method of claim 15, wherein the bacteriophage
selecting
a drug that binds specifically to each subunit of
Phi29 DNA packaging motor comprises 1 copy of genomic
the one or more subunits with a target probability,
dsDNA, and wherein the copy comprises a subunit.
30
wherein the target probability comprises a common
19. The method of claim 15, wherein the bacteriophage
probability for each subunit that the drug delivered to
Phi29 DNA packaging motor comprises 6 copies of packthe
target inactivates the subunit;
aging RNA, and wherein the copies comprise subunits.
describing a relationship between inhibition efficiency of
20. The method of claim 15, wherein the bacteriophage
the drug and total number of the one or more subunits
Phi29 DN~ packaging motor comprises 6 copies of gp16, 35
using a binomial distribution, wherein the inhibition
and wherem the copies comprise subunits.
efficiency comprises a probability that the delivered
~1. The method of claim 15, wherein the bacteriophage
drug blocks the biological function, wherein the inhiPhi29 DNA packaging motor comprises 10,000 copies of
bition efficiency is computed with respect to the miniATP, and wherein the copies comprise subunits.
mum number and the total number;
~2. The_ meth?d of claim 1, wherein the multi-drug 40
confirming
empirically the relationship using an experi~es1stant disease 1s caused by a multidrug-resistant organmental target, wherein the target includes the experiism.
mental target;
23. The method of claim 22, wherein the multidrugadministering the drug to the target to treat a multi-drug
resistant organism is a bacterium, a fungus, a virus, or a
resistant disease, wherein the target comprises a bioparasite.
45
logical complex in a mammalian subject.
24. A method for increasing inhibition efficiency of a
multimeric biocomplex, the method comprising,
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